<SEC-DOCUMENT>0000921895-26-000057.txt : 20260108
<SEC-HEADER>0000921895-26-000057.hdr.sgml : 20260108
<ACCEPTANCE-DATETIME>20260108124201
ACCESSION NUMBER:		0000921895-26-000057
CONFORMED SUBMISSION TYPE:	PRRN14A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20260108
DATE AS OF CHANGE:		20260108

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEA Industries Inc.
		CENTRAL INDEX KEY:			0001482541
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE SERVICES [0700]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				273911608
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		PRRN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41266
		FILM NUMBER:		26518386

	BUSINESS ADDRESS:	
		STREET 1:		385 S. PIERCE AVE, STE C
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		303-993-5271

	MAIL ADDRESS:	
		STREET 1:		385 S. PIERCE AVE, STE C
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Surna Inc.
		DATE OF NAME CHANGE:	20100128

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			YZILabs Management Ltd.
		CENTRAL INDEX KEY:			0002098271
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	98450075EDD8E1AE2D65

	FILING VALUES:
		FORM TYPE:		PRRN14A

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2ND FLOOR, WATER'S EDGE BUILDING
		STREET 2:		WICKHAMS CAY II
		CITY:			ROAD TOWN TORTOLA
		PROVINCE COUNTRY:   	D8
		ZIP:			VG1110
		BUSINESS PHONE:		54-9-11-4082-5010

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2ND FLOOR, WATER'S EDGE BUILDING
		STREET 2:		PO BOX 2429 WICKHAMS CAY II
		CITY:			ROAD TOWN TORTOLA
		PROVINCE COUNTRY:   	D8
		ZIP:			VG1110
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRRN14A
<SEQUENCE>1
<FILENAME>prrn14a14678002_01052026.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">(Rule 14a-101)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>INFORMATION REQUIRED IN CONSENT
STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">Consent Statement Pursuant
to Section 14(a) of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> (Amendment No. 1) </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filed by the Registrant &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filed by a Party other than
the Registrant &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary
Consent Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive
Consent Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive
Additional Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
Material Under Rule 14a-12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; font-size: 10pt">CEA INDUSTRIES INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in; font-size: 10pt">(Name of Registrant as Specified in Its Charter)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">YZILABS MANAGEMENT LTD.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">CHANGPENG ZHAO</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> MAX S. BAUCUS </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> DAVID J. CHAPMAN </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> TERESA MARIE GOODY GUILL&Eacute;N </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> JIAJIN &ldquo;JANE&rdquo;
HE </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> ALEX ODAGIU </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> MATTHEW ROSZAK </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> LING &ldquo;ELLA&rdquo;
ZHANG </P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">(Name of Persons(s) Filing Consent Statement, if Other Than the Registrant)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Payment of Filing Fee (Check
the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
fee required</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fee
paid previously with preliminary materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; color: red"><B>PRELIMINARY COPY SUBJECT
TO COMPLETION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; color: red"> <B>DATED JANUARY
8, 2026</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">YZILABS MANAGEMENT LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">___________, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Fellow BNC Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"> YZILabs Management Ltd. (&ldquo;YZi
Labs Management&rdquo;) and the other participants named herein (collectively, &ldquo;YZi Labs,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo;
or &ldquo;us&rdquo;) beneficially own in the aggregate 4,255,043 shares of common stock, par value $0.00001 per share (the &ldquo;Common
Stock&rdquo;), of CEA Industries Inc., a Nevada corporation (&ldquo;BNC&rdquo; or the &ldquo;Company&rdquo;), representing approximately
9.4% of the outstanding shares of Common Stock. For the reasons set forth in the attached Consent Statement, we believe significant and
immediate changes to the composition of the Board of Directors of the Company (the &ldquo;Board&rdquo;) are necessary to address the
continued destruction of stockholder value at BNC and to ensure that the Company is being run in a manner consistent with your best interest. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"> We are therefore seeking your
support to materially reconstitute the Board by expanding the size of the Board by seven (7) members to thirteen (13) directors in total
and to elect our seven (7) highly-qualified nominees as directors to the Board. We believe BNC stockholders deserve a Board that will
truly look out for stockholders&rsquo; best interest by meaningfully overseeing management, improving investor communications practices
and ensuring management accountability. We therefore feel compelled to take action to provide for a better future for all BNC stakeholders
and to restore the confidence in the Board that stockholders deserve. Accordingly, we urge you to join us in seeking to expand the size
of the Board and elect YZi Lab&rsquo;s seven (7) nominees, Max S. Baucus, David J. Chapman, Teresa Marie Goody Guill&eacute;n, Jiajin
 &ldquo;Jane&rdquo; He, Alex Odagiu, Matthew Roszak and Ling &ldquo;Ella&rdquo; Zhang. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We believe the current Board is
in critical need of additional directors with the knowledge and experience to effectively oversee management, address the Company&rsquo;s
stock price underperformance and operational issues, and restore investors&rsquo; faith in the Company. The stockholders of BNC deserve
a well-functioning Board that understands its role as a steward of stockholder resources. We are therefore launching this consent solicitation
because we believe that stockholders must act <B><U>now</U></B> to prevent the further destruction of shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"> <B>We urge you to carefully
consider the information contained in the attached Consent Statement and then support our efforts by signing, dating and returning the
enclosed WHITE consent card today. The attached Consent Statement and the enclosed WHITE consent card are first being furnished to the
stockholders on or about [<FONT STYLE="font-family: Wingdings">l</FONT>], 2026. We urge you not to sign any revocation of consent card
that may be sent to you by BNC. If you have done so, you may revoke that revocation of consent by delivering a later dated WHITE consent
card to YZi Labs, in care of Saratoga Proxy Consulting, LLC, which is assisting us, at the address listed on the following page, or to
the principal executive offices of BNC. </B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B><BR></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Thank you for your support,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">YZILabs Management Ltd.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: red">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: red"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: red">&nbsp;</P>

<DIV STYLE="padding: 1pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>If you have any questions,
require assistance in voting your <B>WHITE </B>consent card, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>or need additional copies
of YZi Labs&rsquo; consent materials, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>please contact:</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <IMG SRC="image_001.jpg" ALT="Saratoga Proxy Consulting LLC" STYLE="height: 83px; width: 317px"> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>520 8th Avenue, 14th Floor</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>New York, NY 10018</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>(212) 257-1311</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Stockholders call toll-free
at (888) 368-0379</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Email: info@saratogaproxy.com</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; color: red"><B>PRELIMINARY COPY
SUBJECT TO COMPLETION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in; color: red"> <B>DATED JANUARY
8, 2026</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CEA
INDUSTRIES INC.</B></FONT><B><BR>
_________________________<BR>
<BR>
CONSENT STATEMENT<BR>
OF</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">YZILABS MANAGEMENT LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>_________________________<BR>
<BR>
PLEASE SIGN, DATE AND MAIL THE ENCLOSED <U>WHITE</U> CONSENT CARD TODAY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> This Consent Statement
and the accompanying <B>WHITE</B> consent card are being furnished to you as a stockholder of CEA Industries Inc., a Nevada corporation
(&ldquo;BNC&rdquo; or the &ldquo;Company&rdquo;), by YZILabs Management Ltd., a British Virgin Islands business company (&ldquo;YZi Labs
Management&rdquo;) and the other participants named herein (collectively, &ldquo;YZi Labs,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo;
or &ldquo;us&rdquo;), in connection with our solicitation of written consents to expand the size of the Board of Directors of the Company
(the &ldquo;Board&rdquo;) by seven (7) members to thirteen (13) directors in total and elect our seven (7) highly-qualified nominees
as directors to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As significant stockholders
of the Company, with aggregate ownership of 4,255,043 shares of the Company&rsquo;s common stock, par value $0.00001 per share (the &ldquo;Common
Stock&rdquo;), constituting approximately 9.4% of the outstanding shares, we believe that the Board must be materially reconstituted
to ensure that the best interest of stockholders, the true owners of BNC, are appropriately represented in the boardroom. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">A solicitation of written
consents is a process that allows a company&rsquo;s stockholders to act by submitting written consents to any proposed stockholder action
in lieu of voting in person or by proxy at an annual or special meeting of stockholders. We are soliciting written consents from the holders
of shares of the Common Stock to take the following actions (each, as more fully described in this Consent Statement, a &ldquo;Proposal&rdquo;
and together, the &ldquo;Proposals&rdquo;), without a stockholders&rsquo; meeting, as authorized by the Nevada Revised Statutes (the &ldquo;NRS&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Proposal 1 </B>&ndash;
Repeal any provision of the Company&rsquo;s Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;), in effect at the time this Proposal
becomes effective, including any amendments thereto, which were not included in the Bylaws that were in effect and were filed with the
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on July 25, 2025 (the &ldquo;Bylaw Restoration Proposal&rdquo;) to restore
the Bylaws to their previously publicly disclosed form prior to the Board&rsquo;s recent material amendments after the announcement of
this consent solicitation and any other amendments that may be adopted by the Board prior to the completion of this consent solicitation; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Proposal 2</B> &ndash;
Increase the size of the Board by seven (7) directors to thirteen (13) directors in total pursuant to Article II, Section .02 of the
Bylaws (the &ldquo;Board Size Proposal&rdquo;); </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><B>Proposal 3 </B>&ndash;
Amend Article II, Section .04 of the Bylaws to provide stockholders the exclusive ability to fill vacancies resulting from an increase
in the size of the Board by the vote or written consent of the Company&rsquo;s stockholders or by court order (the &ldquo;Vacancy Proposal&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Proposal 4</B> &ndash;
Elect YZi Lab&rsquo;s seven (7) nominees: Max S. Baucus, David J. Chapman, Teresa Marie Goody Guill&eacute;n, Jiajin &ldquo;Jane&rdquo;
He, Alex Odagiu, Matthew Roszak and Ling &ldquo;Ella&rdquo; Zhang, to serve as directors of the Company (the &ldquo;Nominees&rdquo;)
(the &ldquo;Election Proposal&rdquo;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> This Consent Statement
and the enclosed <B>WHITE</B> consent card are first being sent or given to the stockholders of BNC on or about [<FONT STYLE="font-family: Wingdings">l</FONT>],
2026. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We are soliciting your
consent in favor of the adoption of the Board Size Proposal, the Vacancy Proposal and the Election Proposal because we believe the current
Board is in critical need of additional directors with the knowledge and experience in the BNB ecosystem to effectively oversee management,
address the Company&rsquo;s stock price underperformance and operational issues, and restore investors&rsquo; faith in the Company. In
addition, we are soliciting your consent in favor of the adoption of the Bylaw Restoration Proposal to ensure that the incumbent Board
does not limit stockholders&rsquo; ability to act by written consent, or limit the effect of your consent to the expansion of the Board
and the election of the Nominees through changes to the Bylaws not filed with the SEC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The effectiveness of each
of the Proposals requires the affirmative consent of the holders of a majority of the shares of Common Stock outstanding as of the close
of business on the Record Date (as defined below). Each Proposal will be effective without further action when we deliver to BNC such
requisite number of consents. Proposal 1, Proposal 2 and Proposal 3 are not subject to, or conditioned upon, the effectiveness of the
other Proposals. The effectiveness of Proposal 4 is conditioned upon the effectiveness of Proposal 2. If the size of the Board is not
increased, there will be no vacancies to fill, and the Nominees cannot be elected pursuant to Proposal 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In the event that our Nominees
comprise less than a majority of the Board following the Consent Solicitation, there can be no assurance that any actions or changes proposed
by our Nominees will be adopted or supported by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> On [<FONT STYLE="font-family: Wingdings">l</FONT>],
2026, YZi Labs delivered a written request for the Board to fix a record date for determining stockholders entitled to give their written
consent to the Proposals and provided the information required pursuant to the Bylaws. The Company has not yet publicly disclosed the
record date for purposes of determining stockholders entitled to give their written consent to the Proposals (the &#8220;Record Date&#8221;)
or the number of shares of Common Stock outstanding as of the Record Date, each of which is entitled to one consent on each Proposal. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>WE URGE YOU TO ACT TODAY TO
ENSURE THAT YOUR CONSENT WILL COUNT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YZi Labs reserves the right
to submit unrevoked written consents to BNC at any time after the receipt of the signed written consent. See &ldquo;Consent Procedures&rdquo;
for additional information regarding such procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of the date hereof,
YZi Labs collectively owns an aggregate of 4,255,043 shares of Common Stock, representing approximately 9.4% of the outstanding shares
of Common Stock. YZi Labs intends to consent in favor of the Proposals with respect to all of such shares of Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of December 12,
2025, there were 44,062,938 shares of Common Stock, which is the total number of shares outstanding as reported in the Company&rsquo;s
Quarterly Report on Form 10-Q filed with the SEC on December 15, 2025. The mailing address of the principal executive offices of the
Company is 385 South Pierce Avenue, Suite C, Louisville, Colorado 80027. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The failure to sign and
return a consent will have the same effect as voting against the Proposals. Please note that in addition to signing the enclosed WHITE
consent card, you must also date it to ensure its validity.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>THIS CONSENT SOLICITATION
IS BEING MADE BY YZI LABS AND NOT BY OR ON BEHALF OF THE COMPANY. YZI LABS URGES YOU TO SIGN, DATE AND RETURN THE WHITE CONSENT CARD IN
FAVOR OF THE PROPOSALS DESCRIBED HEREIN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Important Notice Regarding
the Availability of Consent Materials for this consent solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>This Consent Statement is
available at [<FONT STYLE="font-family: Wingdings">l</FONT>].com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>IMPORTANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>PLEASE READ THIS CAREFULLY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your shares of Common Stock
are registered in your own name, please submit your consent to us today by signing, dating and returning the enclosed <B>WHITE</B> consent
card in the postage-paid envelope provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> If you hold your shares
in &ldquo;street&rdquo; name with a bank, broker firm, dealer, trust company or other nominee, only they can exercise your right to consent
with respect to your shares of Common Stock and only upon receipt of your specific instructions. Accordingly, it is critical that you
promptly give instructions to consent to the Proposals to your bank, broker firm, dealer, trust company or other nominee. Please follow
the instructions to consent provided on the enclosed <B>WHITE</B> consent card. If your bank, broker firm, dealer, trust company or other
nominee provides for consent instructions to be delivered to them by telephone or Internet, instructions will be included on the enclosed
<B>WHITE</B> consent card. YZi Labs urges you to confirm in writing your instructions to the person responsible for your account and
provide a copy of those instructions to YZi Labs, c/o Saratoga Proxy Consulting, LLC (&ldquo;Saratoga&rdquo;), so that we will be aware
of all instructions given and can attempt to ensure that such instructions are followed.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Execution and delivery of
a consent by a holder of shares of Common Stock will be presumed to be a consent with respect to all shares held by such holder unless
the consent specifies otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only holders of voting securities
of the Company as of the close of business on the Record Date will be entitled to consent to the Proposals. If you are a stockholder as
of the close of business on the Record Date, you will retain your right to consent even if you sell your shares of Common Stock after
the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IF YOU TAKE NO ACTION, YOU
WILL IN EFFECT BE REJECTING THE PROPOSALS. ABSTENTIONS, FAILURES TO CONSENT AND BROKER NON-VOTES WILL HAVE THE SAME EFFECT AS WITHHOLDING
CONSENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 1pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>If you have any questions,
require assistance in voting your <B>WHITE </B>consent card, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>or need additional copies
of YZi Labs&rsquo; consent materials, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>please contact:</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <IMG SRC="image_003.jpg" ALT="Saratoga Proxy Consulting LLC" STYLE="height: 83px; width: 317px"> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>520 8th Avenue, 14th Floor</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>New York, NY 10018</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>(212) 257-1311</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Stockholders call toll-free
at (888) 368-0379</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Email: info@saratogaproxy.com</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>BACKGROUND TO THE SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">The following is a chronology
of our involvement at the Company to date and the material events leading up to this consent solicitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&bull;</TD>
    <TD>On July 28, 2025, the Company announced a $500,000,000 private placement offering (the &ldquo;PIPE&rdquo;), with the support of YZi Labs Management, to establish the Company as the largest publicly listed BNB Chain digital asset treasury strategy in the world.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>Also on July 28, 2025, YZi Labs Management entered into a Securities Purchase Agreement (the &ldquo;Securities Purchase Agreement&rdquo;) and a Registration Rights Agreement (the &ldquo;Registration Rights Agreement&rdquo;) with the Company, each in connection with and to help ensure the successful closing of the PIPE.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On August 5, 2025, the Company announced the closing of the PIPE, that its stock ticker would be changed to &ldquo;BNC,&rdquo;
    and reiterated that the PIPE would support the implementation of the Company&rsquo;s BNB-focused treasury strategy. In connection
    with the closing of the PIPE, the Company entered into an asset management agreement (the &ldquo;Asset Management Agreement&rdquo;)
    with 10X Capital Partners LLC (&ldquo;10X Capital&rdquo;). Also on August 5, 2025, the Company entered into two Strategic Advisor
    Agreements (the &ldquo;Strategic Advisor Agreements&rdquo;) with each of 10X Capital and YZi Labs Management pursuant to which the
    Company engaged 10X Capital and YZi Labs Management to provide ongoing strategic advice and guidance relating to the Company&rsquo;s
    business and operations. Additionally, pursuant to its Strategic Advisor Agreement, 10X Capital received the right to nominate two
    individuals to the Board of Directors of the Company (&ldquo;the Board&rdquo;). Also on August 5, 2025, YZi Labs Management and 10X
    Capital entered into a Strategic Services Agreement pursuant to which YZi Labs Management would provide certain strategic advisory
    services to 10X Capital and receive a portion of the fees earned by 10X Capital under the Asset Management Agreement (the &ldquo;SSA&rdquo;).
    In connection with the closing of the PIPE, the Company issued (i) up to 41,754,478 shares of Common Stock, (ii) pre-funded warrants
    (the &ldquo;Pre-Funded Warrants&rdquo;) to purchase up to 7,750,510 shares of Common Stock with an exercise price per share equal
    to $0.00001, (iii) warrants (the &ldquo;Strategic Advisor Warrants&rdquo;) to purchase up to 5,940,598 shares of Common Stock with
    an exercise price per share equal to $0.00001, (iv)&nbsp;warrants (the &ldquo;Asset Manager Warrants&rdquo;) to purchase up to 990,099
    shares of Common Stock with an exercise price per share equal to $10.23, and (v) warrants (the &ldquo;Stapled Warrants&rdquo;) to
    purchase up to 49,504,988 shares of Common Stock with an exercise price per share equal to $15.15. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>Also on August 5, 2025, in connection with the closing of the PIPE, the Company announced that James R. Shipley, Matthew Tarallo, and Marion Mariathasan resigned as directors of the Company. The Company also announced that pursuant to the Board nomination rights granted by the Company to 10X Capital under its Strategic Advisor Agreement, on August 5, 2025, the Board appointed Hans Thomas, 10X Capital&rsquo;s Founding Partner, and Alexander Monje, 10X Capital&rsquo;s Partner and Chief Legal Officer, as directors of the Company to fill the vacancies created by the resignations.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on August 5, 2025, David Namdar, a Senior Partner at 10X Capital, was appointed by the Board to become the Chief Executive
    Officer of the Company. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On August 7, 2025, representatives of YZi Labs contacted Mr. Thomas regarding their concerns relating to the timing of investor
    updates and to express their views that the Company would benefit from, among other things, a customary online dashboard displaying
    the Company&rsquo;s asset acquisition information and holdings, increased marketing efforts and media presence. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD></TR></TABLE>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"></TD>
    <TD> Since the closing the PIPE through the end of November 2025, representatives
of YZi Labs have sought to privately engage with members of the Board and management of the Company to express their views and concerns
on the Company&rsquo;s performance, operations and management, and to offer their views on the need for the Company to increase its marketing
and media presence and provide more transparency to its stockholders regarding key information on its cryptocurrency holdings and the
employment arrangements of Mr. Namdar, as the Company&rsquo;s CEO. During these discussions, YZi Labs has asked 10X Capital to lower the
asset management fee under the Asset Management Agreement, and has offered on multiple occasions to waive the fees to which YZi Labs Management
was entitled under the SSA, in order to reduce the Company&rsquo;s operational cost and help streamline and boost the performance of the
Company. As of the date of this Consent Statement, 10X Capital has refused to lower the asset management fees under the Asset Management
Agreement, and YZi Labs Management has not received any compensation or any of the key information to which it was entitled under the
SSA. </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On August 14, 2025, representatives of YZi Labs contacted Mr. Thomas
regarding a potential offering and the expected timing of investor updates concerning the Company&rsquo;s BNB treasury.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On August 19, 2025, representatives of YZi Labs again contacted Mr. Thomas regarding their concerns related to the timing
    and substance of investor updates and urged for more timely and informative investor updates. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> On August 20, 2025, representatives of YZi Labs contacted
        Mr. Thomas to express their concerns that the Company would benefit from increased marketing efforts and media presence. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> On August 30, 2025, representatives of YZi Labs contacted
        Mr. Thomas requesting a phone call to discuss their concerns and views related to the timing and substance of the Company&rsquo;s
        public updates to investors and urging for more timely and informative investor updates. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On September 2, 2025, the Company announced that Mr. Monje had resigned from the Board on August 29, 2025, and that the Board had appointed, Dr. Russell Read, the former Chief Investment Officer of 10X Capital to fill the resulting vacancy.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On September 10, 2025, representatives of YZi Labs contacted Messrs.
Thomas and Namdar to convey their serious concerns regarding Messrs. Thomas and Namdar&rsquo;s apparent and active involvement in fundraising
calls promoting another digital asset treasury project. Representatives of YZi Labs also expressed their belief that this may cause investors
to lose faith in the integrity of the Company&rsquo;s management and that the Company needed to promptly address these important concerns.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On September 15, 2025, the Company announced that its quarterly report and earnings announcement for the fiscal quarter ended July 31, 2025 would be delayed.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On September 18, 2025, representatives of YZi Labs introduced Messrs. Thomas and Namdar to potential candidates to join BNC&rsquo;s management that they believed would be beneficial to the Company and would help improve the Company&rsquo;s corporate governance and operations. Mr. Thomas indicated that they were reaching out to their counsel to discuss this possibility.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On September 21, 2025, Mr. Thomas again mentioned that they were going to discuss with their counsel regarding the potential candidates to join BNC&rsquo;s management.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD></TR></TABLE>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> &bull; </TD>
    <TD> On September 25, 2025, representatives of YZi Labs had dinner with Mr. Namdar and other investors at a dinner in Seoul, Korea,
    during which YZi Labs expressed its significant concerns and view that Mr.&nbsp;Namdar needed to allocate more time and attention
    to the management of the Company and its performance. YZi Labs also proposed that, to help lower management cost and burdens to the
    Company, 10X Capital should lower their fees due under the Asset Management Agreement, similar to YZi Lab Management&rsquo;s waiver
    of its fees. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On October 4, 2025, representatives of YZi Labs contacted Mr. Thomas expressing their concerns regarding the Company&rsquo;s
    lack of marketing efforts, and urging the Company to make more fulsome disclosure to its stockholders regarding the amount of BNB
    acquired, and the underperformance of BNC relative to BNB prices. Mr. Thomas indicated that the Company was in the process of discussing
    disclosures with its securities counsel and announcements would be forthcoming. </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Also on October 4, 2025, representatives of YZi Labs contacted
Mr. Thomas to propose that Alex Odagiu, an investment partner at YZi Labs with significant crypto investment experience and extensive
traditional finance background, join the Company in order to improve the Company&rsquo;s management and expressed their concerns about
the management fee continued to be charged by 10X Capital under the Asset Management Agreement, and its impact and burdens on the Company&rsquo;s
operation.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&bull;</TD>
    <TD>On October 7, 2025, the Company announced that on October 1, 2025, the Board increased the size of the Board from four to five members, and appointed Carly E. Howard as a director of the Board, effective immediately.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>Also on October 7, 2025, Mr. Odagiu had a phone call with Mr. Thomas and other representatives of YZi Labs where he expressed his views on how to improve the management of the Company.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On October 8, 2025, Mr. Odagiu followed-up with Mr. Thomas on their discussion and highlighted several governance changes
    that he believed would be well received by stockholders, including management team adjustments, a more effective management
    incentive plan, and potential amendments to the Asset Management Agreement to terms more in line with current market practice,
    including lowering or eliminating fees charged by 10X Capital to the Company in addition to YZi Lab&rsquo;s fee waiver. However, the
    Company refused to add Mr.&nbsp;Odagiu to the management team or adopt his constructive suggestions for the Company. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> On October 17, 2025, representatives of YZi Labs again
        contacted Mr. Thomas regarding their concerns and views on the timing and substance of investor updates and urged for more timely
        and informative investor updates. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>Also on October 17, 2025, the Company announced that it had received a public reprimand letter from the Nasdaq Listing Qualifications Staff pursuant to Nasdaq Listing Rule 5810(c)(4), due to the Company&rsquo;s failure to comply with Nasdaq Listing Rule 5635(b) and that the Company thereafter regained compliance.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On November 6, 2025, YZi Labs sent a letter to the Company demanding that the Company remove and consequently revise its website, The Network (the &ldquo;Website&rdquo;), citing YZi Labs&rsquo; serious concerns regarding potential securities law violations.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD>On November 7, 2025, the Company removed the Website.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">In mid-November 2025, YZi Labs was informed that at a cryptocurrency
conference from November 10 to 12, 2025, Messrs. Namdar and Thomas were again promoting and seeking funding for DATs other than BNC.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD></TR></TABLE>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On November 26, 2025, YZi Labs filed a preliminary consent statement
with the SEC, which was held by the EDGAR system due to technical issues.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Also on November 26, 2025, YZi Labs filed a Schedule 13D
        (the &ldquo;Schedule 13D&rdquo;) disclosing the filing of the preliminary consent statement. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On November 27, 2025, YZi Labs issued a press release announcing the
filing of the preliminary consent statement.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On November 28, 2025, the Company announced that the Board had approved
an increase in the size of the Board from five to six members and had appointed Annemarie Tierney to fill the resulting vacancy, each
effective as of November 26, 2025.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&bull;</TD>
    <TD><P>Also on November 28, 2025, representatives of the Company contacted representatives of YZi Labs regarding YZi Labs&rsquo;
Schedule 13D and press release.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On November 30, 2025, Matthew Roszak had a call with director Annemarie Tierney during which he provided background about YZi
    Labs, its substantive role in the BNB Chain ecosystem and the background of the investment in the Company by YZi Labs and followers
    of YZi Labs. Mr. Roszak also noted the general under-performance of the Company and his concerns regarding the potential conflict of
    interest of 10X Capital. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 1, 2025, Teresa Goody Guill&eacute;n had a call with Ms.
Tierney during which Ms. Goody Guill&eacute;n also discussed YZi Labs&rsquo; background and its investment in the Company. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 1, 2025, YZi Labs filed its preliminary consent statement with the SEC. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 2, 2025, YZi Labs Management issued a formal Notice and Demand for Corrective Action to 10X Capital (the &ldquo;10X
    Notice&rdquo;) alleging threatened violations of the SSA, mismanagement by 10X Capital, including threatened abandonment of the BNB
    Treasury Strategy, and demanding that 10X Capital provide written confirmation of corrective action by December 5, 2025. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 3, 2025, YZi Labs issued a press release announcing the delivery of the 10X Notice and cautioning stockholders
    of the Company regarding the value-destructive actions of 10X Capital. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 4, 2025, the Company issued a press release acknowledging YZi Lab&rsquo;s consent statement and recent communications. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 5, 2025, counsel to 10X Capital sent a letter to YZi Labs
Management responding to the 10X Notice. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 5, 2025, counsel to Ms. Tierney, Nick Etten, Dr.
Read and Carly Howard, the four purportedly &ldquo;independent&rdquo; directors of the Company (the &ldquo;Independent Directors&rdquo;),
was introduced to YZi Labs. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD></TR></TABLE>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> &bull; </TD>
    <TD> On December 6, 2025, the Independent Directors&rsquo; counsel and
a representative of YZi Labs, together with Ms. Goody Guill&eacute;n, had a call in which they discussed the general position of the parties
and YZi Labs&rsquo; requests for management and performance improvements at the Company. During this call, the Independent Directors&rsquo;
counsel stated the Independent Directors&rsquo; openness to YZi Labs&rsquo; concerns and hopes for an open dialogue with YZi Labs in which
there would be no surprises. Further to this initial call, the Independent Directors&rsquo; counsel and representatives of YZi Labs continued
to have calls to explore possible joint efforts towards a constructive path of addressing the concerns of YZi Labs and other stockholders. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 9, 2025, the Independent Directors&rsquo; counsel indicated
on short notice to YZi Labs that external defense counsel retained by the Company would like to join a conference call with representatives
of YZi Labs. YZi Labs responded that it would like to have its own external counsel present for a call with the Company&rsquo;s external
counsel, and requested alternate times. YZi Labs received no alternative times or further response concerning scheduling this call. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 11, 2025, YZi Labs Management delivered a notice of termination of the SSA to 10X Capital. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> On December 12, 2025, YZi Labs and counsel for the Independent
        Directors engaged in a conference call during which YZi Labs expressed its concerns regarding the Company, including certain
        apparent disclosure failures and 10X Capital&rsquo;s potential conflicts of interest. On the call, counsel to the Independent
        Directors indicated that the Independent Directors would consider YZi Labs&rsquo; concerns. YZi Labs again proposed that Alex
        Odagiu serve as replacement interim CEO, given his profound capital markets background and native familiarity to the BNB ecosystem,
        both of which would be tremendously valuable to BNC as a BNB DAT. The Independent Directors&rsquo; counsel responded that his
        clients believed that Mr. Odagiu, despite having insight into the BNB ecosystem, lacked sufficient experience on U.S. public
        company boards to serve as CEO. YZi Labs expressed its disagreement with this statement. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 12, 2025, in the spirit of open dialogue, YZi Labs
notified the Independent Directors&rsquo; counsel that, among other matters, YZi Labs would soon be sending certain communications to
the full Board, including (i) a letter requesting the inspection of certain stockholder list materials, (ii) a letter requesting immediate
Board attention to address certain filing deficiencies and (iii) a letter regarding the conflicts of interest of 10X Capital and requesting
immediate remedial actions by the Board. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 12, 2025, YZi Labs Management delivered a letter to the Board requesting the inspection of certain stockholder
    list materials and related information pursuant to Section 78.105 of the NRS (the &ldquo;First Stockholder List Demand&rdquo;). </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 12, 2025, YZi Labs Management sent a letter to the Board expressing its concerns regarding apparent numerous
    disclosure failures and deficiencies it had identified in filings made by the Company with the SEC, and requesting remediation (the
    &ldquo;Disclosure Deficiencies Letter&rdquo;). </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD></TR></TABLE>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> &bull; </TD>
    <TD> On December 13, 2025, YZi Labs Management sent a letter to the Board
expressing its serious concerns regarding apparent material conflicts of interest involving Mr. Namdar as CEO and Mr.&nbsp;Thomas as director
due to their dual and continuing roles at 10X Capital and the Company (the &ldquo;Conflict Letter&rdquo;). The Conflict Letter requested
that the Board take immediate and decisive corrective actions, including Mr. Namdar&rsquo;s removal as CEO and the appointment of an interim
CEO with no affiliation with 10X Capital, amendment of the Asset Management Agreement to market and customary terms, the recusal of Messrs.
Namdar and Thomas from Company deliberations related to matters related to 10X Capital and YZi Labs, and the formation of an independent
investigation committee to review Messrs. Namdar and Thomas&rsquo; conduct at the Company. As of the date of this Consent Statement, YZi
Labs has received no response to the Conflict Letter. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> Also on December 13, 2023, representatives of YZi Labs Management forwarded the First Stockholder List Demand, the Disclosure
    Deficiencies Letter and the Conflict Letter to the Independent Directors&rsquo; counsel. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &bull; </TD>
    <TD> On December 15, 2025, YZi Labs communicated with the Independent Directors&rsquo;
counsel to reinforce YZi Labs&rsquo; position that familiarity with the BNB Chain ecosystem is important for the CEO or interim CEO of
the Company. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"> &nbsp;&nbsp; </P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 15, 2025, the Company
                                            filed its Quarterly Report on Form 10-Q with the SEC, which announced that as of December
                                            12, 2025, the number of its outstanding shares of Common Stock had increased to 44,062,938
                                            (the &ldquo;Share Increase&rdquo;). </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 16, 2025, YZi Labs communicated with the Independent Directors&rsquo;
counsel to express its concerns with and surprise over the Share Increase and noted that it had learned that other investors wished to
speak with the Company and the Board regarding their perspectives. YZi Labs also notified the Independent Directors&rsquo; counsel that
any amendment to the Company&rsquo;s Bylaws or any other actions by the Board that could impact or ultimately reduce voting rights or
other fundamental stockholder rights would be viewed poorly by the Company's stockholders. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt; text-align: justify; text-indent: 0in"> </P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 17, 2025, counsel to the Company delivered a letter to
counsel to YZi Labs rejecting the First Stockholder List Demand because YZi Labs&rsquo; individual ownership had ceased to exceed 5% based
on the Share Increase. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 17, 2025, the Independent
                                            Directors&rsquo; counsel delivered a letter to YZi Labs responding to the Disclosure Deficiencies
                                            Letter. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> On
                                            December 18, 2025, YZi Labs communicated with the Independent Directors&rsquo; counsel to
                                            express its disappointment with the Company&rsquo;s rejection of the First Stockholder Demand
                                            based on a technicality that was not publicly disclosed as of the date the First Stockholder
                                            Demand was delivered to the Company. YZi Labs also expressed to the Independent Directors&rsquo;
                                            counsel its view that the actions of YZi Labs were taken in the best interests of the Company
                                            and its stockholders. </P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                        <TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD></TD><TD STYLE="text-align: justify"> During these communications, YZi Labs also inquired about the status
of the Board&rsquo;s reply to the Conflict Letter, and discussed with the Independent Directors&rsquo; counsel its intent to amend the
preliminary consent statement it had previously filed with the SEC and its imminent plan to form a stockholder group that would own at
least 5% of the Common Stock in order to resubmit a demand for stockholder lists under Nevada law, as well as file an amendment to its
Schedule 13D accordingly. The Independent Directors&rsquo; counsel stated that the Board would view the amendment of YZi Labs&rsquo; consent
statement as &ldquo;unnecessary&rdquo; and an &ldquo;escalation.&rdquo; </P></TD></TR>
                                                                                                        </TABLE>



<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 19, 2025, the Independent Directors&rsquo; counsel held
a call with internal counsel for YZi Labs wherein they discussed YZi Labs&rsquo; consent solicitation and potential changes to the Board.
After the Independent Directors&rsquo; counsel asked that YZi Labs refrain from amending its consent statement during the holiday season,
YZi Labs asked the Independent Directors&rsquo; counsel to urge the Board to make a plan, to be shared with all stockholders, to address
the concerns that YZi Labs had previously provided regarding management, the Asset Management Agreement, and 10X Capital&rsquo;s conflicts
of interest. The Independent Directors&rsquo; counsel stated that it was unlikely that the Board or Company management could commit to
any time frame in the near term. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 19, 2025, YZi Labs and the Nominees entered into
the Group Agreement (as defined and described below). </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 19, 2025, Ms. Howard and Mr. Namdar each filed a
Form 3 with the SEC, which had failed to be filed in the required timeframes upon their appointments to the Board. The failure to file
such Form 3s within the prescribed timeframes, including after the issuance of warrants to Mr. Namdar in August 2025, was among the filing
deficiencies pointed out by YZi Labs in the Disclosure Deficiency Letter. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 22, 2025, YZi Labs reached out to the Independent Directors&rsquo;
counsel to request a call and an update on the (i) amendments to the Asset Management Agreement and addressing of 10X Capital's conflicts
of interest, (ii) potential appointment of Alex Odagiu as interim CEO of the Company and (iii) the views of the Independent Directors
regarding potential changes to the structure of the Board. The Independent Directors&rsquo; counsel rejected the request for the call
and informed YZi Labs that the Independent Directors were working on addressing the Asset Management Agreement, but that they were not
currently interested in bringing on Alex Odagiu as interim CEO. The Independent Directors&rsquo; counsel further asked YZi Labs to provide
a job description for the role of CEO and an overall plan for the Company. </TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD> &nbsp;</TD><TD> </TD><TD STYLE="text-align: justify"> YZi Labs noted in response that the Company had thus far failed to
articulate a clear strategic plan and requested that such a plan be prepared and disclosed to all stockholders. The Independent Directors&rsquo;
counsel indicated that the Independent Directors would consider this request. </TD></TR>
                                                                                                                                                    </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 23, 2025, YZi Labs filed an amendment to its Schedule
13D disclosing the Group Agreement and the formation of the Group (as defined below), which collectively beneficially owns more than 5%
of the Company&rsquo;s outstanding shares. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On the evening of December 28, 2025, the Company issued a press release
announcing that on December 26, 2025, it had adopted a stockholder rights agreement (the &ldquo;Poison Pill&rdquo;) and amendment and
restatement to its Bylaws (the &ldquo;Bylaw Amendments&rdquo;). The Poison Pill and Bylaw Amendments have the effect of adding significant
administrative and procedural hurdles to the process of nominating director candidates to the Board and soliciting the written consent
of stockholders of the Company. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 28, 2025, YZi Labs reached out to the Independent Directors&rsquo; counsel to
                                                                   express its surprise and disappointment at the sudden announcement of the Poison Pill and the Bylaw Amendments, which the Company
                                                                   stated in its press release were in direct response to the formation of the Group. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On December 29, 2025, the members of the Group who own shares beneficially
or of record (the &ldquo;Requesting Stockholders&rdquo;) delivered a letter to the Board requesting the inspection of certain stockholder
list materials and related information pursuant to Section 78.105 of the NRS (the &ldquo;Second Stockholder List Demand&rdquo;). </TD></TR></TABLE>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> Also on December 29, 2025, in order to comply with the new requirements
under the Bylaw Amendments regarding the nomination of director candidates to the Board and the solicitation of the written consent of
stockholders of the Company pursuant to the Bylaw Amendments, YZi Labs, in its capacity as a holder of record of shares of the Company,
and Ms. Ling Zhang, in her capacity as a proposed director nominee, delivered a letter to the Company requesting all guidelines and policies
of the Company generally applicable to directors, and an electronic copy of the form of questionnaire and the form of representation and
agreement referenced in the Bylaw Amendments. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On January 3, 2026, counsel to the Company responded to the Second
Stockholder List Demand requesting that the Requesting Stockholders provide evidence of their beneficial ownership of Common Stock and
that the Requesting Stockholders execute a confidentiality agreement (the &ldquo;Stockholder List NDA&rdquo;) before the Company would
agree to provide the requested stockholder list materials. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"> &bull; </TD><TD STYLE="text-align: justify"> On January 5, 2026, YZi Labs issued a
                                            press release responding to the Company&rsquo;s adoption of the Poison Pill and the Bylaw
                                            Amendments, expressing its disappointment in the apparent efforts of the Board to entrench
                                            itself rather than continue an open and productive dialogue regarding the advancement of
                                            stockholder interests. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                 <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&bull; </P></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> On
                                            January 6, 2026, the Independent Directors&rsquo; counsel reached out to YZi Labs, stating
                                            his client&rsquo;s view that YZi&rsquo;s December 23, 2025 Schedule 13D amendment disclosing
                                            the Group was a surprise, which led to the Company and the Board&rsquo;s adoption of the
                                            Poison Pill and Bylaw Amendments. Counsel to the Independent Directors also stated that YZi
                                            should cease its PR campaign and alleged that YZi&rsquo;s Jan 5, 2026 press release reacting
                                            to the Poison Pill and Bylaw Amendments contained untruthful information. </P>
                                                                                                                                                     <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>
                                                                                                                                                     <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> A
                                            representative of YZi Labs replied to counsel to the Independent Directors by clarifying
                                            that YZi Labs had previously notified such counsel as early as December 18, 2025 that it
                                            intended to form a group that owned at least 5% of the Common Stock in order to resubmit
                                            a demand for stockholder lists under Nevada law. As previously communicated to the Independent
                                            Directors&rsquo; counsel, YZi Lab&rsquo;s formation of the Group was in direct response to
                                            YZi Labs&rsquo; being involuntarily diluted down below 5% due to the Share Increase and the
                                            rejection of the First Stockholder List Demand. </P>
                                                                                                                                                     <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>
                                                                                                                                                     <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> In
                                            addition, a representative of YZi Labs highlighted to the Independent Directors&rsquo; counsel
                                            that in the spirit of a constructive dialogue YZi Labs did not file its revised consent statement
                                            during the holiday season, despite the fact that the Independent Directors&rsquo; counsel
                                            did not indicate a proposed plan or any timeline to improve Company management, amend the
                                            Asset Management Agreement or address 10X Capital&rsquo;s apparent conflicts of interest
                                            as previously requested by YZi Labs. A representative of YZi Labs further expressed its views
                                            that (i) the Company and the Board&rsquo;s failure to recognize YZi Labs&rsquo; attempts
                                            engage constructively in a timely manner and decision to instead focus their time and attention
                                            on the adoption of the Poison Pill and the Bylaw Amendments, which impede stockholder rights
                                            and add substantial costs to the Company and its ultimate owners, its stockholders, are extremely
                                            disappointing, and (ii) the press release issued by YZi Labs on January 5, 2026 contains
                                            truthful statements and YZi Labs will take all appropriate actions to protect stockholder
                                            interests in light of the recent Poison Pill and Bylaw Amendments recently adopted by the
                                            Board. </P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                 <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&bull; </P></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> Also
                                            on January 6, 2026, representatives of YZi Labs sent an email to the Board following up on
                                            the Conflict Letter, requesting clarity as to (i) the expected timing for a substantive written
                                            response and (ii) the concrete actions and timeline the Board intends to pursue to address
                                            the issues identified in the Conflict Letter, including amendments to the Asset Management
                                            Agreement and the ongoing and structural conflicts of interest at the Company and Board level. </P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                 <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&bull; </P></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> Also
                                            on January 6, 2026, counsel to the Requesting Stockholders sent comments to the Stockholder
                                            List NDA to counsel to the Company. </P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                 <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&bull; </P></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> Also
                                            on January 6, 2026, the Company filed a Current Report on Form 8-K with the SEC, announcing
                                            that Dr. Read resigned as a member of the Board effective January 1, 2026. The Company further
                                            disclosed that it intends to fill the vacancy on the Board resulting from Dr. Read&rsquo;s
                                            departure. </P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                 <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&bull; </P></TD><TD STYLE="text-align: justify"> On
                                            January 8, 2026, YZi Labs filed this revised consent statement with the SEC. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>QUESTIONS AND ANSWERS ABOUT
THIS CONSENT SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are some of
the questions you, as a stockholder, may have and answers to those questions. The following is not meant to be a substitute for the information
contained in the remainder of this Consent Statement, and the information contained below is qualified by the more detailed descriptions
and explanations contained elsewhere in this Consent Statement. We urge you to carefully read this entire Consent Statement prior to making
any decision on whether to grant any consent hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHO IS MAKING THE SOLICITATION?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YZi Labs is making this solicitation.
See &ldquo;Additional Participant Information&rdquo; for additional information regarding the Participants (as defined below) in this
consent solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHAT ARE THE PROPOSALS FOR
WHICH CONSENTS ARE BEING SOLICITED?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are asking you to consent
to four corporate actions: (1) the Bylaw Restoration Proposal, (2) the Board Size Proposal, (3) the Vacancy Proposal, and (4) the Election
Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> YZi Labs is asking
you to consent to the Board Size Proposal, the Vacancy Proposal and the Election Proposal to expand the size of the Board by seven (7)
directors and to elect our seven (7) Nominees to fill the resulting vacancies. In addition, in order to ensure that you have the ability
to act by written consent and that your consent to elect the Nominees will not be modified or diminished by actions taken by the incumbent
Board, YZi Labs is asking you to consent to the Bylaw Restoration Proposal.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHY ARE WE SOLICITING YOUR
CONSENT?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are soliciting your consent
because we believe the current Board is in critical need of additional directors with the knowledge and experience to effectively oversee
management, address the Company&rsquo;s stock price underperformance and operational issues, and restore investors&rsquo; faith in the
Company. We believe this consent solicitation is the best option we have available as stockholders to reject the status quo and correct
the Company&rsquo;s trajectory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have identified highly
qualified candidates we believe would be able to serve the best interest of all stockholders by maximizing BNC&rsquo;s value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHO ARE THE NOMINEES?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We are asking you to
elect each of Max S. Baucus, David J. Chapman, Teresa Marie Goody Guill&eacute;n, Jiajin &ldquo;Jane&rdquo; He, Alex Odagiu, Matthew
Roszak and Ling &ldquo;Ella&rdquo; Zhang as a director of BNC. The business experience of our highly qualified Nominees is set forth
in this Consent Statement under the section entitled &ldquo;Proposal 4 &ndash; The Election Proposal,&rdquo; which we urge you to read. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHAT IF NOT ALL OF THE PROPOSALS
ARE APPROVED?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the election of any
of our Nominees pursuant to this Consent Solicitation is contingent on the passage of the Board Size Proposal, the opposite is not true
 &ndash; the Bylaw Restoration Proposal, the Board Size Proposal and the Vacancy Proposal is not contingent upon the election of any of
our Nominees through this Consent Solicitation. A Nominee will not be elected pursuant to the Election Proposal if such Nominee does not
receive the affirmative consent of the holders of a majority of the outstanding shares in favor of such Nominee&rsquo;s election, even
if one or more of the other Nominees are each duly elected pursuant to the Election Proposal by a separate affirmative consent of the
holders of a majority of the outstanding shares in favor of one or more of such other Nominees&rsquo; election. If the Board Size Proposal
has been passed and one or more of the Nominees is not elected to the Board, one or more vacancies will remain on the Board following
the conclusion of the Consent Solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHO IS ELIGIBLE TO GRANT
WRITTEN CONSENTS IN FAVOR OF THE PROPOSALS?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Stockholders of voting
securities at the close of business on the Record Date have the right to consent to the Proposals. On [<FONT STYLE="font-family: Wingdings">l</FONT>],
2026, YZi Labs delivered a written request for the Board to fix the Record Date. The Company has not yet disclosed the new Record Date
or the number of shares of Common Stock outstanding as of the Record Date, each of which is entitled to one consent on each Proposal.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHEN IS THE DEADLINE FOR
SUBMITTING CONSENTS?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We urge you to submit
your consent as soon as possible. In order for the Proposals to be adopted, pursuant to the Bylaws, the Company must receive written
unrevoked consents signed by a sufficient number of stockholders to adopt the Proposals within sixty (60) days of the earliest dated
valid consent delivered to the Company. YZi Labs delivered its written consent to the Company on [<FONT STYLE="font-family: Wingdings">l</FONT>],
2026. Consequently, YZi Labs will need to deliver properly completed and unrevoked written consents from the holders of a majority
of the outstanding voting securities as of the close of business on the Record Date by no later than [<FONT STYLE="font-family: Wingdings">l</FONT>].
Nevertheless, we intend to set [<FONT STYLE="font-family: Wingdings">l</FONT>] as the goal for submission of written consents. Effectively,
this means that you have until [<FONT STYLE="font-family: Wingdings">l</FONT>] to consent to the Proposals. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WE URGE YOU TO ACT AS SOON
AS POSSIBLE TO ENSURE THAT YOUR CONSENT WILL COUNT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>HOW MANY CONSENTS MUST BE
RECEIVED IN ORDER TO ADOPT THE PROPOSALS?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Proposals will be adopted
and become effective when properly completed, unrevoked consents are signed by the holders of a majority of the outstanding Common Stock
as of the close of business on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHAT SHOULD YOU DO TO SUPPORT
OUR PROPOSALS?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your shares of Common Stock
are registered in your own name, please submit your consent to us by signing, dating and returning the enclosed <B>WHITE</B> consent card
in the postage-paid envelope provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> If you hold your shares
in &ldquo;street&rdquo; name with a bank, broker firm, dealer, trust company or other nominee, only they can exercise your right to consent
with respect to your shares of Common Stock and only upon receipt of your specific instructions. Accordingly, it is critical that you
promptly give instructions to consent to the Proposals to your bank, broker firm, dealer, trust company or other nominee. Please follow
the instructions to consent provided on the enclosed <B>WHITE</B> consent card. If your bank, broker firm, dealer, trust company or other
nominee provides for consent instructions to be delivered to them by telephone or Internet, instructions will be included on the enclosed
<B>WHITE</B> consent card. We urge you to confirm in writing your instructions to the person responsible for your account and provide
a copy of those instructions to YZi Labs, c/o Saratoga, so that we will be aware of all instructions given and can attempt to ensure
that such instructions are followed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>WHOM SHOULD YOU CALL IF YOU
HAVE QUESTIONS ABOUT THE SOLICITATION?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Please contact Saratoga
Proxy Consulting, LLC as set forth below. </P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 1pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>If you have any questions,
require assistance in voting your <B>WHITE </B>consent card, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>or need additional copies
of YZi Labs&rsquo; consent materials, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>please contact:</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <IMG SRC="image_004.jpg" ALT="Saratoga Proxy Consulting LLC" STYLE="height: 83px; width: 317px"> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>520 8th Avenue, 14th Floor</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>New York, NY 10018</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>(212) 257-1311</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Stockholders call toll-free
at (888) 368-0379</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Email: info@saratogaproxy.com</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REASONS FOR OUR SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WE BELIEVE THAT IMMEDIATE
AND MATERIAL CHANGE TO THE BOARD AND COMPANY MANAGEMENT IS REQUIRED TO UNLOCK SIGNIFICANT VALUE FOR ALL STOCKHOLDERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>YOU HAVE AN OPPORTUNITY TO
SEND THE BOARD AND MANAGEMENT <U>A LOUD AND CLEAR MESSAGE </U>THAT STOCKHOLDERS WILL NOT TOLERATE THE VALUE-DESTRUCTIVE STATUS QUO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a firm which invests
in companies with strong fundamentals and significant potential for long-term value creation. We are a significant stockholder of the
Company and a key contributor to the overall BNB ecosystem, who participated in the successful closing of the Company&rsquo;s $500,000,000
PIPE this summer because we believe in the Company&rsquo;s remarkable growth potential and the strength of its announced BNB-focused treasury
strategy. Although we have great hopes for the Company&rsquo;s future, we have become extremely concerned about the Company&rsquo;s underperformance
since the closing of the PIPE and fear that under the current leadership, stockholders will continue to watch their investment decline
until it is too late to put the Company back on the right path.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>We Believe Company Management
is Directly Responsible for the Company&rsquo;s Poor Performance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite its advantageous market
position and strong fundamentals, BNC has significantly underperformed on several levels. Since the closing of the PIPE, the Company&rsquo;s
share price has significantly underperformed, despite the fact that the value of BNB, the primary asset of the Company&rsquo;s digital
asset treasury, has increased over the same time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image1.jpg" ALT="A graph showing the growth of a company&#10;&#10;AI-generated content may be incorrect." STYLE="height: 355px; width: 626px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, BNB has outperformed
other major digital assets since the beginning of 2025, which makes the Company&rsquo;s poor performance an apparent outlier and even
more concerning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image2.jpg" ALT="A graph of a line graph&#10;&#10;AI-generated content may be incorrect." STYLE="height: 346px; width: 621px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given that BNB, the Company&rsquo;s
digital asset treasury&rsquo;s primary asset is performing well, and the Company has an advantageous market position, especially with
YZi Labs Management being a significant investor in the Company, we believe that the Company&rsquo;s underperformance is primarily due
to its poor strategic execution, lack of media and marketing presence and an erosion of investor confidence in current management &ndash;
all of which has occurred with CEO, David Namdar at the Company&rsquo;s helm. For example, we were surprised and extremely concerned that
the Company took more time than any other similarly situated digital asset treasury (&ldquo;DAT&rdquo;) company in issuing its shelf registration
statement with respect to its at-the-market-offering (&ldquo;ATM&rdquo;), and thus failed to deliver its ATM on time, which we believe
is one of the most important factors driving DAT flywheel.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
For context, the Company promised investors that it would file its resale registration statement within 30 days following the closing
date of the PIPE, but it did not file until 53 days following the closing date. While we consented to an extension to the deadline to
file the initial registration statement under the Registration Rights Agreement in order to ensure the registration of the securities,
the Company&rsquo;s inability to timely complete fairly typical corporate actions integral to a public company, in our view, raises serious
concerns regarding company management and their ability to execute. To make matters worse, while these filings were pending, in our view
the Company repeatedly refused to provide sufficient communication with its investors, keeping them in the dark with respect to the liquidity
of and use of proceeds in connection with their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Company Management
has Repeatedly Failed to Engage the Market and Sufficiently Promote Itself and its Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the Company
has not been sufficiently transparent with its stockholders regarding its actions, timing and has made little to no media or marketing
efforts to promote its assets. For instance, the Company has failed to alleviate the significant confusion amongst investors between BNB
Network Company and CEA Industries &ndash; the use of two names has created a lack of clarity which we believe needs to be corrected promptly.
Further, the Company has neglected to prepare several customary resources for stockholders to understand the Company&rsquo;s assets or
governance. In the almost four months since the closing of the PIPE, the Company has still not finished its Investor Relations webpage.
Additionally, the Company has failed to provide timely and meaningful updates regarding its NAV/NAV per share, mNAV, BNB yield generation
or BNB accumulation for several months. The Company only recently announced the launch of its treasury dashboard, a key investor communication
tool, which we urged the Company to adopt months ago, and which currently provides basic and materially insufficient information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Source: BNC, BMNR, SBET, ETHZ, FWDI, HSDT and STSS SEC filings.</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been very little
media coverage on the Company, as there has been little to no activity on X (Twitter) or on other social media platforms, which we feel
is unusual for a DAT company. We believe the Company&rsquo;s apparent inability to adequately and effectively communicate with its investors
and the market further exacerbates investor confusion and significantly contributes to the Company underperformance. In the world of cryptocurrency,
marketing is of the utmost importance, and we believe there is no way for the Company to reach its true potential, without effective and
comprehensive marketing or investor outreach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>We Believe Management&rsquo;s
and Directors&rsquo; Interests are Not Aligned with Stockholders, and the Board has Failed in its Duty to Actively Oversee Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our view, the interests
of Company management and the Board simply do not align with the interests of its stockholders. In particular, we have become concerned
regarding the inability of the Board and management to objectively monitor and manage the services being provided by 10X Capital, the
Company&rsquo;s asset manager, and its apparent failure to act independently in the best interest of the Company. Director Hans Thomas
is one of 10X Capital&rsquo;s Founding Partners, Director Russell Read is 10X Capital&rsquo;s former Chief Investment Officer and CEO
David Namdar is a Senior Partner at 10X Capital. We have serious concerns regarding Messrs. Thomas and Namdar&rsquo;s loyalty and amount
of dedication to the Company, as on more than one occasion, these individuals have significantly promoted other potential DATs, despite
failing to adequately promote BNC and BNB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are concerned that Mr.
Namdar is more focused on serving the interests of 10X Capital, rather than advocating for the interests of all BNC stockholders. We also
have serious concerns that the Board as currently constituted lacks the experience or conviction to hold management accountable. In our
view, the Board also lacks sufficient the digital asset expertise necessary to drive and oversee the necessary strategic changes at the
Company. We believe that stockholders <B><U>need change now</U></B> and that the best way to ensure that the Company has the tools and
oversight necessary to improve its performance and restore investors&rsquo; faith in the Company is by adding additional competent, experienced
directors that can effectively lead the Company and oversee management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>A New Qualified Chief
Executive Officer and Experienced Management Team is Necessary </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon our experience,
a company cannot reach its full potential without a competent and committed CEO and a properly structured executive team. In addition
to the concerns regarding Mr. Namdar&rsquo;s performance and lack of devotion and loyalty to the Company, we believe BNC lacks an experienced
leadership team capable of supporting and executing the Company&rsquo;s strategy. The Company&rsquo;s continued refusal to include qualified
senior talent further undermines its capacity to deliver on its stated objectives. We believe that Mr. Namdar is simply unable and/or
unwilling to perform at the level necessary to execute upon BNC&rsquo;s current strategic initiatives and effectively lead BNC. Accordingly,
we believe that, if elected, the reconstituted Board should promptly undertake a thorough review of Mr.&nbsp;Namdar&rsquo;s performance
and should explore the selection of a new CEO with the expertise, commitment and independence necessary to lead the Company into the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>The Path Forward:
We Believe New Competent and Experienced Directors are Needed in the Boardroom NOW</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We believe that time is of
the essence. Stockholders cannot afford the leadership of the current Board and management team. We urge all BNC stockholders to act
now to expand the size of the Board and add our experienced competent director nominees to effectively oversee management, address the
Company&rsquo;s stock price underperformance and operational issues, in order to maximize value for all stockholders &ndash; the true
owners of BNC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROPOSAL 1 &ndash; THE BYLAW
RESTORATION PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We are asking you to
consent to the adoption of the Bylaw Restoration Proposal to ensure that the incumbent Board does not limit your ability to act by written
consent or limit the effect of your consent to increase the size of the Board to thirteen (13) directors and elect the Nominees to fill
such newly created directorships through changes to the Bylaws not filed with the SEC on or before July 25, 2025, which have the effect
of limiting existing stockholders&rsquo; rights and abilities to take action in their capacity as stockholders of BNC. The following
is the text of the Bylaw Restoration Proposal: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> &ldquo;RESOLVED, that
any provision of the Amended and Restated Bylaws of CEA Industries Inc. as of the effectiveness of this resolution that was not included
in the Bylaws, as amended filed with the Securities and Exchange Commission on July 25, 2025, be and is hereby repealed.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> The purpose of the
Bylaw Restoration Proposal is to restore the Bylaws of the Company to their publicly available form prior to the announcement of this
consent solicitation. Since the incumbent Board materially amended the current form of the Bylaws on December 26, 2025 through the Bylaw
Amendments, the Bylaw Restoration Proposal, if adopted, will repeal the Bylaw Amendments and any other amendments adopted prior to the
completion of this consent solicitation, and restore the Bylaws to the version that was publicly available in filings by BNC with the
SEC on July 25, 2025, without considering the nature of the changes the incumbent Board has adopted. As a result, the Bylaw Restoration
Proposal could have the effect of repealing bylaw amendments that one or more stockholders of the Company may consider to be beneficial
to them or to the Company. However, the Bylaw Restoration Proposal will not preclude the Board from reconsidering any repealed bylaw
changes following the conclusion of the consent solicitation. The Bylaw Restoration Proposal will have the effect of repealing the Bylaw
Amendments. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>YZI LABS URGES YOU TO CONSENT
TO THE BYLAW RESTORATION PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<BR STYLE="clear: both">
<B>PROPOSAL 2 &ndash; THE BOARD SIZE PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We are asking you to
consent to the Board Size Proposal to increase the size of the Board by seven (7) directors to thirteen (13) directors in total. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The following is the text
of the Board Size Proposal:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> &ldquo;RESOLVED, that
the size of the Board of Directors of CEA Industries Inc. is increased by seven (7) directors to thirteen (13) directors in total pursuant
to Article II, Section .02 of the Bylaws, as amended.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">If the number of directors
currently serving on the Board is not expanded, we do not believe there will be any vacancies for which our Nominees can be elected to
fill. Accordingly, the Election Proposal is conditioned upon the approval by the stockholders of this Board Size Proposal.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>YZI LABS URGES YOU TO CONSENT
TO THE BOARD SIZE PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>PROPOSAL 3 &ndash; THE VACANCY
PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are asking you to consent
to the Vacancy Proposal to divest the current directors of their ability to fill vacancies on the Board resulting from an increase in
the size of the Board pursuant to a vote by or the written consent of the Company&rsquo;s stockholders or by court order, and to provide
stockholders with the exclusive ability to fill vacancies resulting from an increase in the size of the Board pursuant to a vote by or
the written consent of the Company&rsquo;s stockholders or by court order. Amending Article II, Section .04 of the Bylaws, as set forth
on <U>Schedule II</U> of this Consent Statement, will ensure that the stockholders have the exclusive ability to elect the directors to
fill the vacancies resulting from the Board Size Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>YZI LABS URGES YOU TO CONSENT
TO THE VACANCY PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROPOSAL 4 &ndash; THE ELECTION
PROPOSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe the current
Board is in critical need of additional directors with the knowledge and experience to effectively oversee management, as discussed in
further detail in the &ldquo;Reasons for the Solicitation&rdquo; section of this Consent Statement. Accordingly, YZi Labs is asking you
to consent to elect, without a stockholders&rsquo; meeting, each of the following individuals to serve as a director of the Company:
Max S. Baucus, David J. Chapman, Teresa Marie Goody Guill&eacute;n, Jiajin &ldquo;Jane&rdquo; He, Alex Odagiu, Matthew Roszak and Ling
 &ldquo;Ella&rdquo; Zhang. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> The Board is currently
composed of five (5) directors and one (1) vacancy, all of whom are elected annually. If the Board Size Proposal is approved, then the
Board will be increased to thirteen (13) directors with seven (7) vacancies. All of the Nominees, if elected, would fill those vacancies
and each would hold office until the next annual meeting of stockholders and until such person&rsquo;s successor has been elected or
until such person&rsquo;s death, resignation, retirement or removal. If the Board Size Proposal is approved and each of the Nominees
is elected, then the Nominees will constitute a majority of the Board. There is no assurance that any of the Company&rsquo;s incumbent
directors will serve as directors if any of the Nominees are elected. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE NOMINEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
sets forth the name, age, business address, present principal occupation, and employment and material occupations, positions, offices,
or employments for the past five years of each of the Nominees. The specific experience, qualifications, attributes and skills that led
us to conclude that the Nominees should serve as directors of the Company is set forth in the bios below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Max S. Baucus</B>,
age 84, has served as Co-Founder of Baucus Group LLC, a consulting firm, since January 2017, as well as The Baucus Institute, a public
policy institute at the University of Montana School of Law, since May 2017. Mr. Baucus has also served as a strategic advisor to the
board of directors of Chagee Holdings Limited (NASDAQ: CHA), a globally recognized premium tea brand from China, since July 2024. Additionally,
Mr. Baucus has served as an advisor to several technology, biotech and manufacturing companies, including Tonix Pharmaceuticals, since
April 2017, Alibaba, from 2017 to 2018 and Hikvision Digital Technology Com., Ltd., from July 2020 to July 2025. Mr. Baucus previously
served as an Advisor to Binance Holdings Ltd., a cryptocurrency exchange, from February 2021 to November 2023, where he also served as
Chairman of the Binance Global Advisory Board from September 2022 to November 2023. In 2014, then-U.S. President Barack Obama nominated
Mr. Baucus to be Ambassador of the United States of America to the People&rsquo;s Republic of China, a position he held until 2017. Mr.
Baucus formerly served as the senior United States Senator from Montana from 1978 to 2014 and was Montana&rsquo;s longest serving U.S.
Senator. While in the Senate, Mr. Baucus served as Chairman and Ranking Member of the Senate Committee on Finance, as well as Chairman
of the Joint Committee on Taxation and Subcommittee on Transportation and Infrastructure, and also as a member of the Senate Committee
on Agriculture, Nutrition and Forestry and the Senate Committee on Environment and Public Works. Before his election to the U.S. Senate,
Mr. Baucus represented Montana in the U.S. House of Representatives from 1975 to 1978. Earlier in his career, Mr. Baucus served as a
staff member in the Division of Corporation Finance of the SEC from 1968 to 1971. Mr. Baucus has served as a member of the board of directors
of AirJoule Technologies Corporation (NASDAQ: AIRJ), a water harvesting technology company, since March 2021 and DIH Holding US, Inc.
(NASDAQ: DHAI), a global medical technology and robotics company, since August 2023. Previously, Mr. Baucus served as a member of the
board of directors of Ingram Micro Holding Corporation (NYSE: INGM), a global distributor of information technology products from May
2017 to July 2021. Mr. Baucus received a B.A. in Economics from Stanford University, as well as a J.D. from Stanford Law School. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Mr.
Baucus&rsquo; decades of public service, including his extensive leadership experience across government, international diplomacy, and
both domestic and international trade, coupled with his advisory work with emerging technologies and financial markets, make him a valuable
addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>David J. Chapman</B>,
age 45, has served as a member of the Advisory Board of Hex Trust, an institutional-grade digital asset custodian providing custody,
DeFi, brokerage, and financing solutions for financial institutions, digital asset organizations, corporations, and private clients,
since March 2025, and as a member of the Bitcoin Visionary Council, a technology council for DDC Enterprise Limited (NYSE: DDC), an innovative
global Asian food platform, since September 2025. Previously, Mr. Chapman served as Co-Founder and Executive Director of OSL Group (&ldquo;OSL
Group&rdquo;) (f/k/a BC Technology Group Limited) (HKSE: 0863), a digital asset platform which provides prime brokerage, custody, exchange
and SaaS services for institutional clients and professional investors, from August 2018 to January 2024, and as a Board Advisor, from
January 2024 to July 2024. From June 2016 to July 2020, Mr. Chapman served as Co-Founder and Executive Chairman of Octagon Strategy Ltd.,
a private investment firm specializing in commodity and digital asset trading across international markets. Prior to that, Mr. Chapman
served as Co-Founder and Chief Operating Officer of ANX International Ltd., a financial technology company and blockchain solutions provider,
from 2013 to 2018. Earlier in his career, Mr. Chapman served in several positions in the banking industry, including as Head of Futures
and Options - Front Office Development at HSBC Holdings PLC (NYSE: HSBC), a banking and financial services organization, from 2010 to
2013, Market Access Design and Projects Manager at ABN AMRO Bank N.V. (OTCMKTS: AAVMY), a Dutch universal bank which provides retail,
private, and commercial banking products and services, from 2009 to 2010, Senior Application Analyst at Barclays Capital PLC (NYSE: BCS),
a registered broker-dealer and futures commission merchant that offers a broad range of financial services to institutional clients,
from 2008 to 2009, Trading Systems Analyst at Credit Suisse Group AG (formerly, NYSE: CS), a global financial services company which
offered wealth management and investment banking services, in 2008, and Trading Systems Consultant at Bear Stearns Companies, Inc. (formerly,
NYSE: BSC), a brokerage and investment firm, from 2005 to 2008. Mr. Chapman earned a Bachelor&rsquo;s Degree in Information Systems from
Australian Catholic University (Brisbane Campus). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that that
Mr. Chapman&rsquo;s extensive executive leadership experience spanning across the digital asset infrastructure, financial technology,
and global capital sectors, together with his demonstrated success in founding and scaling regulated digital-asset and blockchain companies
and his financial background, make him a valuable addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Teresa Marie Goody
Guill&eacute;n</B>, age 49, has served as a Partner at Baker &amp; Hostetler LLP, a full-service law firm, since 2019, where she is the
leader of the firm&rsquo;s Digital and Innovative Markets practice and co-leader of its Web3 and Digital Assets team, and is nationally
recognized for her work in securities enforcement, corporate governance, digital assets and emerging financial technologies. Prior to
that, Ms.&nbsp;Goody Guill&eacute;n served as the Founder and Chief Executive Officer of The Goody Group LLC and Goody Counsel PLLC,
a consulting firm and affiliated law firm which offered a full range of business and legal services, from 2015 to 2019. Ms. Goody Guill&eacute;n
also served as a Senior Advisor to Kalorama Partners LLC (&ldquo;Kalorama&rdquo;), a business consulting firm, from 2015 to 2017, after
serving as the Chief Operating Officer and Managing Director of Kalorama and its affiliated law firm, Kalorama Legal Service, PLLC, from
2011 to 2015. From 2009 to 2011, Ms. Goody Guill&eacute;n served as an attorney in the U.S. Securities and Exchange Commission&rsquo;s
Office of the General Counsel. Earlier in her career, Ms. Goody Guill&eacute;n served as an attorney at McDermott Will and Emery LLP
(n/k/a McDermott Will &amp; Schulte UK LLP), a global law firm, from 2006 to 2009, and was a Judicial Law Clerk for the Honorable Ricardo
M. Urbina of the U.S. District Court for the District of Columbia, from 2004 to 2005. Ms. Goody Guill&eacute;n has served as Co-Chair
of The Digital Chamber&rsquo;s Token Alliance, a leading industry initiative by The Digital Chamber (f/n/a the Chamber of Digital Commerce)
focusing on advocating for a clear, pro-growth legal and regulatory environment for digital assets and tokenization, beginning in 2024.
Ms. Goody Guill&eacute;n also previously served as an Adjunct Professor at Georgetown University, a private university, where she taught
Digital Law and Policy, during the 2023-2024 academic year. Ms. Goody Guill&eacute;n received a B.S. in Business Administration from
George Mason University, a J.D. from Georgetown University Law Center, and an M.B.A. from Georgetown University McDonough School of Business. </P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Ms.
Goody Guill&eacute;n&rsquo;s extensive legal experience representing public companies, boards and executives with respect to securities
law, capital markets transactions and corporate governance, along with her executive and operational experience, and financial and digital
sector expertise, will make her a valuable addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Jiajin &ldquo;Jane&rdquo;
He</B>, age 35, has served as a General Partner of YZiLabs Management Ltd., an investment firm focused on the digital asset, blockchain,
Web3, AI, and biotech sectors, since March 2025, where she sources and evaluates investment opportunities, leads due diligence, negotiates
and executes investments, and provides strategic guidance to portfolio companies on scaling, fundraising, and operations. Previously,
Ms. He served as Chief Operation Officer and an Investment Analyst at Apeiron Capital Limited, a long-biased equity hedge fund, from
March 2021 to February 2025. Prior to that, Ms. He served as an Associate Director at PAAMCO Prisma, LLC, an alternative asset management
firm specializing in creating globally diversified hedge fund solutions for institutional investors, from 2017 to August 2020, where
she was responsible for fund investment and portfolio management. Ms. He received a Bachelor of Economics degree from Tsinghua University
and an M.B.A. degree from Stanford University. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Ms.
He&rsquo;s extensive leadership experience across investment management and financial services in both the traditional financial industry
and digital currency asset fields, coupled with her deep expertise in the digital-asset, blockchain, and emerging-technology sectors,
makes her well-qualified to serve on the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Alex Odagiu</B>,
age 34, has served as an Investment Partner of YZiLabs Management Ltd., an investment firm focused on the digital asset, blockchain,
Web3, AI, and biotech sectors, since September 2025, where he identifies and evaluates high-potential investment opportunities, conducts
due diligence, structure deals, and presents recommendations, provides strategic guidance to portfolio companies on scaling, fundraising,
and operations, and builds relationships with founders, investors, and partners. Mr. Odagiu previously served as an Investment Director
of YZi Labs from January 2022 to September 2025, as well as an Investment Manager from September 2021 to December 2021. Prior to that,
Mr. Odagiu served as an Associate at Letterone Technology (UK) LLP, an affiliate of Letterone Investment Holdings SA, an investment firm
focused on the technology sector, from 2019 to January 2021. Mr. Odagiu began his career at Goldman Sachs International, an affiliate
of The Goldman Sachs Group, Inc. (NYSE: GS), a multinational investment bank and financial services company, where he served in the Investment
Banking Division as an Associate from 2016 to 2018, as well as an Analyst from 2014 to 2016. Mr. Odagiu received an M.A. (Hons) in Economics
and Mathematics from the University of St Andrews. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Mr.
Odagiu&rsquo;s investment experience across digital assets, particularly the BNB ecosystem, as well as his institutional investing and
corporate finance experience, coupled with his work on large-scale technology and financial services transactions and advising public
and public-ready companies on capital allocation, risk management, and strategic decisions, make him a valuable addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Matthew Roszak</B>,
age 53, has served as a Co-Founder and Chairman of each of Bloq, Inc., a blockchain infrastructure and enterprise technology company,
since December 2015, as well as Hemi Labs, Inc., a Bitcoin DeFi and programmability platform, since February 2024. Mr. Roszak also currently
serves as the Founding Partner of Tally Capital, LLC, a private investment firm focused on crypto, AI, and biotech, since June 2014,
and as a General Partner of Off The Chain Capital, LLC, a digital asset investment fund, since August 2019. In addition, Mr. Roszak currently
serves as the Chairman of the Advisory Board of The Digital Chamber, a global blockchain trade association, since June 2014. Mr. Roszak
previously served as a member of the board of directors of 180 Connect, Inc. (formerly TSX: NCT.U), a national provider of digital integration
and satellite installation services, from 2002 to 2006. Mr. Roszak received a B.A. in Economics from Lake Forest College. </P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Mr.
Roszak&rsquo;s extensive experience in the blockchain and financial technology industries, coupled with his regulatory, policy and governance
expertise, as well as his public board experience, make him a valuable addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <B>Ling &ldquo;Ella&rdquo;
Zhang</B>, age 43, has served as Managing Partner and Head of YZiLabs Management Ltd., an investment firm focused on the digital asset,
blockchain, Web3, AI, and biotech sectors, since January 2025. Ms. Zhang has also served as President of Shop Social, Inc. (Trendsi),
an AI-powered supply chain and fashion B2B platform, since January 2025, and where she previously served as Co-Founder and Chief Executive
Officer from 2020 to December 2024. Previously, Ms. Zhang served as Founder of Binance Labs, the former venture arm of Binance, the world&rsquo;s
leading crypto exchange, and the predecessor to YZi Labs, from 2018 to 2019. Prior to that, Ms. Zhang served as Co-Founder and a member
of the board of directors of Chengdu Xiaoduo Technology, an AI-powered customer service and enterprise automation solutions company,
from 2014 to 2020. Earlier in her career, Ms. Zhang served as an Investment Principal of Kleiner Perkins Caufield &amp; Byers (n/k/a
Kleiner Perkins), a leading venture capital firm focused on incubation, early stage and growth companies, from 2010 to 2015; a Key Account
Manager at Google Inc., a global technology company, from 2008 to 2010; and a Senior Marketing Manager of Tencent Holdings Limited, an
internet and technology company where she was the founding member of Tencent e-commerce, from 2005 to 2008. Ms. Zhang received a B.S.E.E
in Electrical and Electronics Engineering from the University of Electronic Science and Technology of China and an M.B.A. from Stanford
University Graduate School of Business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> We believe that Ms.
Zhang&rsquo;s leadership experience and technical expertise in investment, asset management, and financial services, spanning both traditional
markets and the digital asset industry, combined with her strong grounding in financial oversight, investment management, and corporate
governance, will make her a valuable addition to the Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> The principal business
address of Mr. Baucus is c/o Baucus Group LLC, 257 Blue Roan Lane, Belgrade, MT 59714. The principal business address of Mr. Chapman
is c/o Easy Star Consultants, Office 2113, 19/F, 33 Wyndham Street, Central, Hong Kong. The principal business address of Ms. Goody Guill&eacute;n
is BakerHostetler LLP, Washington Square, Suite 1100, 1050 Connecticut Avenue NW, Washington, DC 20036. The principal business address
of each of Mses. He and Zhang and Mr. Odagiu is 2<SUP>nd</SUP> Floor Water&rsquo;s Edge Building, Wickhams Cay II, Road Town, Tortola,
VG 1110, British Virgin Islands. The principal business address of Mr. Roszak is 167 North Green Street, Chicago, Illinois 60607. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Each of Messrs. Baucus
and Roszak and Ms. Goody Guill&eacute;n is a citizen of the United States of America. Each of Messrs. Chapman and Odagiu is a citizen
of the United Kingdom. Each of Mr. Chapman and Ms. Goody Guill&eacute;n is also a citizen of Australia. Ms. He is a citizen of China.
Mr. Odagiu is also a citizen of Moldova and Romania. Mr. Roszak is also a citizen of Poland. Ms. Zhang is a citizen of Singapore. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of the date hereof,
Messrs. Baucus, Chapman and Roszak and Mses. Goody Guill&eacute;n and Zhang do not own beneficially or of record any securities of the
Company and have not entered into any transactions in securities of the Company during the past two years. </P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of the date
hereof, Ms. He may be deemed to beneficially own 2,099,644 shares of Common Stock, consisting of (i) 911,524 shares of Common Stock directly
beneficially owned and (ii) 1,188,120 shares of Common Stock underlying certain Stapled Warrants. As of the date hereof, Mr.&nbsp;Odagiu
may be deemed to beneficially own 4,918 shares of Common Stock. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Mr. Odagiu is
a member of Goldmount III a series of Allocations 2025 Master, LLC, a Delaware limited liability company (&ldquo;Allocations&rdquo;),
which participated in the PIPE and beneficially owns securities of the Company. As the result of the foregoing relationships Mr. Odagiu
may be deemed to have an economic interest in certain of the securities of the Company held by Allocations. Mr. Odagiu has neither voting
nor investment power with respect to any of the securities of the Company held by Allocations, nor does he have the right to acquire
such voting or investment power within 60 days. Allocations is not party to the Group Agreement, and the Group has not agreed to act
together with Allocations for the purpose of acquiring, holding, voting or disposing of any securities of the Company. As such, Allocations
is not a Participant in this solicitation. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Ms. Goody Guill&eacute;n
is an indirect member of Arche Capital SPV IV LLC, a Delaware limited liability company (&ldquo;Arche&rdquo;), which participated in
the PIPE and beneficially owns securities of the Company. As the result of the foregoing relationships Ms. Goody Guill&eacute;n may be
deemed to have an indirect economic interest in certain of the securities of the Company held by Arche. Ms. Goody Guill&eacute;n has
neither voting nor investment power with respect to any of the securities of the Company held by Arche, nor does she have the right to
acquire such voting or investment power within 60 days. Arche is not party to the Group Agreement, and the Group has not agreed to act
together with Arche for the purpose of acquiring, holding, voting or disposing of any securities of the Company. As such, Arche is not
a Participant in this solicitation. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> For information
regarding transactions in securities of the Company by the Nominees during the past two years, see <U>Schedule III</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Each of the Nominees
may be deemed to be a member of a &ldquo;group&rdquo; with the other participants in this solicitation for the purposes of Section 13(d)(3)
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such group may be deemed to beneficially own
the 4,255,043 shares of Common Stock beneficially owned in the aggregate by all of the Participants. Each of the Nominees specifically
disclaims beneficial ownership of shares of Common Stock that he or she does not directly own. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Each of the Nominees
has consented to being named as a nominee of YZi Labs Management in any consent solicitation statement filed by YZi Labs Management and
serving as a director of the Company if elected. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Each of the Nominees
(other than Ms. Zhang) has granted Ms. Zhang powers of attorney to execute certain SEC filings and other documents in connection with
the consent solicitation statement. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="line-height: 107%">On
December 19, 2025, YZi Labs Management and the Nominees (collectively, the &ldquo;Group&rdquo;) entered into a Group Agreement. Pursuant
to the terms of the Group Agreement, the parties agreed, among other things, </FONT>(i) to the joint filing of statements on Schedule
13D on behalf of each of them with respect to the securities of the Company to the extent required by applicable law, (ii) to working
together to enhance stockholder value at the Company, including seeking representation on the Board, (iii) to solicit written consents
to, among other things, expand the size of the Board and to elect certain persons nominated for election to the Board (including those
nominated by or on behalf of YZi Labs Management), (iv) that each Nominee would not enter into any transactions in the securities of
the Company without the prior written consent of YZi Labs Management, (v) YZi Labs Management would bear all approved expenses incurred
in connection with the Group&rsquo;s activities, and (vi) to take all other action necessary to achieve the foregoing. </P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As disclosed elsewhere
herein, each of Mses. He and Zhang and Mr. Odagiu is an employee of YZi Labs Management. In connection with their employment, Mses. He
and Zhang and Mr. Odagiu receive compensation from YZi Labs Management, such compensation is independent of and not in connection with
their nomination as a director candidate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As disclosed
elsewhere herein, Ms. Goody Guill&eacute;n is an attorney and Partner at BakerHostetler LLP. In connection with such position, since
2025, Ms. Goody Guill&eacute;n has provided legal services to YZi Labs Management. Ms. Goody Guill&eacute;n has also served as a
mentor to YZi Labs Management&rsquo;s incubator program since 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> On July 28, 2025, in
connection with the PIPE, Ms. He entered into a Securities Purchase Agreement and Registration Rights Agreement, pursuant to which she
purchased 1,188,120 shares of Common Stock and 1,188,120 Stapled Warrants, and received certain registration rights in connection with
the PIPE. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> YZi Labs believes that
each Nominee presently is, and if elected as a director of the Company, each of the Nominees would qualify as, an &ldquo;independent
director&rdquo; within the meaning of (i) applicable NASDAQ listing standards applicable to board composition, including NASDAQ Listing
Rule 5605(a)(2), and (ii)&nbsp;Section 301 of the Sarbanes-Oxley Act of 2002. Notwithstanding the foregoing, YZi Labs acknowledges that
no director of a NASDAQ listed company qualifies as &ldquo;independent&rdquo; under the NASDAQ listing standards unless the board of
directors affirmatively determines that such director is independent under such standards. Accordingly, YZi Labs acknowledges that if
any Nominee is elected, the determination of such Nominee&rsquo;s independence under the NASDAQ listing standards ultimately rests with
the judgment and discretion of the Board. No Nominee is a member of the Company&rsquo;s compensation, nominating or audit committee that
is not independent under any such committee&rsquo;s applicable independence standards.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Election Proposal to elect
the Nominees is conditioned upon the effectiveness of the Board Size Proposal. If the size of the Board is not increased pursuant to the
Board Size Proposal, there will be no vacancies to fill, and none of the Nominees can be elected pursuant to the Election Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have no reason
to believe that any of the Nominees will be unable or unwilling to serve as directors, if any of the Nominees are not available for election,
YZi Labs may designate such other nominee or nominees to be elected to the Board. In any such case, we would identify and properly designate
such substitute nominees in an amended Consent Statement and shares of Common Stock represented by the enclosed <B>WHITE</B> consent card
will be voted for such substitute nominee(s). Each of the Nominees has agreed to be named in this Consent Statement and to serve as a
director of the Company, if elected. The <B>WHITE</B> consent card delivered with this Consent Statement provides each stockholder with
the opportunity to approve the Election Proposal in part by designating the names of any of the Nominees whom such stockholder does not
want elected to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> If all of the Nominees
are elected through the Election Proposal, they will constitute a majority of the Board, and then a change of control of the Board may
be deemed to have occurred under certain of the Company&rsquo;s material agreements and contracts. Based on a review of the Company&rsquo;s
publicly available material contracts and agreements, such a change of control may trigger certain change of control provisions or payments
in the Company&rsquo;s following material contracts and agreements: (i) Loan Agreement between CEAD Panda Lender LLC and the Company
(the &ldquo;Loan Agreement&rdquo;); (ii) the 2017 Equity Incentive Plan; (iii) the 2021 Equity Incentive Plan; and (iv) the Executive
Employment Agreement by and between the Company and Anthony K. McDonald (the &ldquo;McDonald Employment Agreement&rdquo;). </P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Pursuant to the Loan
Agreement, the occurrence of a &ldquo;Change in Control&rdquo; would constitute an &ldquo;Event of Default&rdquo; (each as defined in
the Loan Agreement), and CEAD Panda Lender LLC would be able to accelerate&nbsp;the &ldquo;Loan&rdquo; and demand&nbsp;immediate payment&nbsp;of
all &ldquo;Indebtedness&rdquo; (each as defined in the Loan Agreement) (principal, interest, fees, costs) and enforce remedies&nbsp;under
the Loan Agreement and applicable law, including exercising rights against the collateral under the security documents. However, pursuant
to the terms of the Loan Agreement, the &ldquo;Maturity Date&rdquo; (as defined in the Loan Agreement) occurred on December 4, 2025 and
the entire principal amount then outstanding under the Loan Agreement, together with all accrued but unpaid interest, is currently due
and payable by the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Pursuant to the 2017
Equity Incentive Plan, upon a &ldquo;Change in Control&rdquo; (as defined in the 2017 Equity Incentive Plan) of the Company, the Compensation
Committee of the Board may provide vesting acceleration or other protective features in any individual &ldquo;Award Agreement&rdquo;
(each as defined in the 2017 Equity Incentive Plan). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Pursuant to the 2021
Equity Incentive Plan, upon a &ldquo;Change in Control&rdquo; (as defined in the 2021 Equity Incentive Plan) of the Company, outstanding
awards do not automatically accelerate unless an &ldquo;Award Agreement&rdquo; provides otherwise (each as defined in the 2021 Equity
Incentive Plan). The Compensation Committee of the Board may provide&nbsp;accelerated vesting, exercisability&nbsp;or other protections
in any individual Award Agreement tied to a Change in Control. The 2021 Equity Incentive Plan automatically terminates on the tenth anniversary
of its adoption date (April 4, 2029), or earlier if the share reserve is exhausted. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Pursuant to the McDonald
Employment Agreement, upon the consummation of a &ldquo;Change in Control&rdquo;, any remaining unvested options under Mr. McDonald&rsquo;s
 &ldquo;Second Award&rdquo; (each as defined in the McDonald Employment Agreement) vest in full; provided that, for purposes of the Second
Award, any change in the composition of the Board within one (1) year following a &ldquo;Qualified Offering&rdquo; (as defined in the
McDonald Employment Agreement) does not constitute a Change in Control. According to the Company&rsquo;s SEC filings, Mr. McDonald was
awarded stock options to purchase 3,772 shares of common stock under the 2021 Stock Award Plan, that was approved by stockholders, with
an exercise price of $88.20 per share, the price of a share of common stock on the day immediately prior to the signing of the McDonald
Employment Agreement. The vesting of the options is at the rate of one-third on each of the date of the signing of the McDonal Employment
Agreement (November 24, 2021) and the first and second anniversary of the signing of the McDonald Employment Agreement. The option, once
vested, is exercisable for ten years from the date the employment contract was signed. Pursuant to the McDonald Employment Agreement,
the vesting of Mr. McDonald&rsquo;s stock options will be accelerated upon a change of control of the Company. </P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Except as otherwise
set forth in this consent statement (including the Schedules hereto), (i) during the past 10 years, none of the Nominees has been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no Nominee directly or indirectly beneficially
owns any securities of the Company; (iii) no Nominee owns any securities of the Company which are owned of record but not beneficially;
(iv) no Nominee has purchased or sold any securities of the Company during the past two years; (v) no part of the purchase price or market
value of the securities of the Company owned by any Nominee is represented by funds borrowed or otherwise obtained for the purpose of
acquiring or holding such securities; (vi) no Nominee nor any of his or her associates is, or within the past year was, a party to any
contract, arrangements or understandings with any person with respect to any securities of the Company, including, but not limited to,
joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits,
or the giving or withholding of proxies; (vii) no associate of any Nominee owns beneficially, directly or indirectly, any securities
of the Company; (viii) no Nominee owns beneficially, directly or indirectly, any securities of any affiliate of the Company; (ix) no
Nominee nor any of his or her affiliates, associates or immediate family members was a party to any transaction, or series of similar
transactions, since the beginning of the Company&rsquo;s last fiscal year, or is a party to any currently proposed transaction, or series
of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, which transaction has materially affected
or will materially affect the Company or any of its affiliates or in which the amount involved exceeds $120,000; (x) no Nominee nor any
of his or her associates has any arrangement or understanding with any person with respect to any future employment by the Company or
its affiliates, or with respect to any future transactions to which the Company or any of its affiliates will or may be a party; (xi)
no Nominee or any of their respective associates has a substantial or material interest, direct or indirect, by securities holdings or
otherwise in any matter to be acted on through the consent solicitation, other than the election of directors; (xii) no Nominee holds
any positions or offices with the Company; (xiii) no Nominee has a family relationship with any director, executive officer, or person
nominated or chosen by the Company to become a director or executive officer; and (xiv) no companies or organizations, with which any
of the Nominees has been employed in the past five years, is a parent, subsidiary or other affiliate of the Company. There are no material
proceedings to which any Nominee or any of his or her associates is a party adverse to the Company or any of its subsidiaries or has
a material interest adverse to the Company or any of its subsidiaries. Except as disclosed herein, with respect to each of the Nominees,
(a) none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K occurred during the past ten years, (b) there are no relationships
involving any Nominee or any Nominee&rsquo;s associates that would have required disclosure under Item 407(e)(4) of Regulation S-K had
such Nominee been a director of the Company, and (c) none of the Nominees nor any of their associates has received any fees earned or
paid in cash, stock awards, option awards, non-equity incentive plan compensation, changes in pension value or nonqualified deferred
compensation earnings or any other compensation from the Company during the Company&rsquo;s last completed fiscal year, or was subject
to any other compensation arrangement described in Item 402 of Regulation S-K.&nbsp; </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Other than as
set forth in this consent statement, there are no agreements, arrangements or understandings between the members of the Group or any
other person or persons pursuant to which the nomination of the Nominees described herein is to be made, other than the consent by each
Nominee to be named in this consent statement and to serve as a director of the Company if elected. Other than as stated herein, none
of the Nominees is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any
of its subsidiaries in any material pending legal proceeding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"> <B>YZI LABS STRONGLY URGES
YOU TO CONSENT TO THE ELECTION OF ALL SEVEN (7) OF THE NOMINEES&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">CONSENT PROCEDURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Section 78.320 of the
NRS provides that, absent a contrary provision in a Nevada corporation&rsquo;s certification of incorporation or bylaws, any action required
or permitted to be taken at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent
thereto is signed by stockholders holding at least a majority of the voting power, except that if a different proportion of voting power
is required for such an action at a meeting, then that proportion of written consents is required. Article III of the Bylaws provides
that any corporate action required by the Company&rsquo;s Articles of Incorporation, Bylaws, or under the NRS, to be voted upon or approved
at a duly called meeting of the shareholders, may be accomplished without a meeting if a written memorandum setting forth the action
so taken, shall be signed by holders of a majority of the total outstanding shares of Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> For the Proposals to
be adopted, pursuant to the Bylaws, the Company must receive written unrevoked consents signed by a sufficient number of stockholders
to adopt the Proposals within sixty (60) days of the earliest dated valid consent delivered to the Company. YZi Labs delivered its written
consent to the Company on [<FONT STYLE="font-family: Wingdings">l</FONT>], 2026. Consequently, YZi Labs will need to deliver properly
completed and unrevoked written consents from the holders of a majority of the outstanding voting securities as of the close of business
on the Record Date by no later than [<FONT STYLE="font-family: Wingdings">l</FONT>]. Nevertheless, we intend to set [<FONT STYLE="font-family: Wingdings">l</FONT>]
as the goal for submission of written consents. WE URGE YOU TO ACT TODAY TO ENSURE THAT YOUR CONSENT WILL COUNT. We reserve the right
to submit to BNC consents at any time within sixty (60) days of the earliest dated valid consent delivered to BNC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Proposals become effective
as a result of this Consent Solicitation, the Company will be required to disclose the effectiveness of the stockholder actions within
four business days by filing a Current Report on Form 8-K with the SEC. YZi Labs also intends to notify stockholders as promptly as possible
by press release of the results of the Consent Solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Appraisal/Dissenter Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Stockholders are not entitled
to appraisal or dissenters&rsquo; rights under Nevada law in connection with the Proposals or this Consent Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Revocation of Written Consents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> An executed consent
card may be revoked at any time by delivering a written consent revocation before the time that the action authorized by the executed
consent becomes effective. Revocations may only be made by the holder that granted such consent. A revocation may be in any written form
validly signed by the holder as long as it clearly states that the consent previously given is no longer effective. The delivery of a
subsequently dated <B>WHITE</B> consent card that is properly executed will constitute a revocation of any earlier consent. The revocation
may be delivered either to YZi Labs, in care of Saratoga, or to the principal executive offices of BNC. Although a revocation is effective
if delivered to BNC, YZi Labs requests that either the original or photostatic copies of all revocations of consents be mailed or delivered
to YZi Labs, c/o Saratoga, at the address set forth on the back cover of this Consent Statement, so that YZi Labs will be aware of all
revocations and can more accurately determine if and when sufficient unrevoked consents to the actions described in this Consent Statement
have been received. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Procedural Instructions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may consent to any of
the Proposals on the enclosed <B>WHITE </B>consent card by marking the &ldquo;CONSENT&rdquo; box and signing, dating and returning the
<B>WHITE </B>consent card in the envelope provided. You may also vote against consenting with respect to any one or more of the Proposals
on the enclosed <B>WHITE </B>consent card by marking the &ldquo;AGAINST CONSENT&rdquo; box, and signing, dating and returning the <B>WHITE
</B>consent card in the envelope provided. You may abstain from consenting to any of the Proposals on the enclosed <B>WHITE </B>consent
card by marking the &ldquo;ABSTAIN&rdquo; box and signing, dating and returning the <B>WHITE </B>consent card in the envelope provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you sign, date and return
the <B>WHITE </B>consent card, but give no direction with respect to certain of the Proposals, you will be deemed to consent to any such
Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please note that in addition
to signing the enclosed <B>WHITE </B>consent card, you must also date it to ensure its validity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>YZI LABS URGES YOU TO CONSENT
TO <U>ALL</U> OF THE PROPOSALS ON THE ENCLOSED WHITE CONSENT CARD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SOLICITATION OF CONSENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The solicitation of consents
pursuant to this consent solicitation is being made by YZi Labs Management and the other Participants named herein. Consents may be solicited
by mail, facsimile, telephone, Internet, in person and by advertisements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> YZi Labs Management
has entered into an agreement with Saratoga for solicitation and advisory services in connection with this solicitation, for which Saratoga
will receive a fee not to exceed $[<FONT STYLE="font-family: Wingdings">l</FONT>], together with reimbursement for its reasonable out-of-pocket
expenses, and will be indemnified against certain liabilities and expenses, including certain liabilities under the federal securities
laws. Saratoga will solicit consents from individuals, brokers, banks, bank nominees and other institutional holders. YZi Labs Management
has requested banks, brokerage houses and other custodians, nominees and fiduciaries to forward all solicitation materials to the beneficial
owners of the shares of Common Stock they hold. YZi Labs Management will reimburse these holders for their reasonable out-of-pocket expenses
in so doing. It is anticipated that Saratoga will employ approximately [<FONT STYLE="font-family: Wingdings">l</FONT>] persons to solicit
BNC stockholders as part of this solicitation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The entire expense of this
consent solicitation is being borne by YZi Labs Management. Costs of this consent solicitation are currently estimated to be approximately
$[<FONT STYLE="font-family: Wingdings">l</FONT>]. YZi Labs Management estimates that through the date hereof its expenses in connection
with this consent solicitation are approximately $[<FONT STYLE="font-family: Wingdings">l</FONT>]. The actual amount could be higher or
lower depending on the facts and circumstances arising in connection with the solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YZi Labs intends to seek reimbursement
from BNC of all expenses it incurs in connection with the solicitation. YZi Labs does not intend to submit the question of such reimbursement
to a vote of security holders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ADDITIONAL PARTICIPANT INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The participants in this solicitation
are YZi Labs Management, Changpeng Zhao, and each of the Nominees (each, a &ldquo;Participant&rdquo; and collectively, the &ldquo;Participants&rdquo;).
YZi Labs Management is a British Virgin Islands business company. Mr. Zhao is a citizen of Canada and the United Arab Emirates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal business of
YZi Labs Management is to invest in securities and fuel impact in Web3, AI and biotech. The principal business of Mr. Zhao is serving
as an entrepreneur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal business address
of each of YZi Labs Management and Mr. Zhao is 2<SUP>nd</SUP> Floor Water&rsquo;s Edge Building, Wickhams Cay II, Road Town, Tortola,
VG 1110, British Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of the date hereof,
YZi Labs Management directly beneficially owns 2,150,481 shares of Common Stock. Mr. Zhao, as the sole director of YZi Labs Management,
has voting and investment control of the shares held by YZi Labs Management and may be deemed to be the beneficial owner of such shares.
Mr. Zhao disclaims any beneficial ownership of such securities not directly owned by him. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Excluded from YZi Labs
Management&rsquo;s beneficial ownership as disclosed herein are (i) 7,750,510 shares of Common Stock underlying certain Pre-Funded Warrants,
(ii) 9,900,991 shares of Common Stock underlying certain Stapled Warrants and (iii) 3,564,359 shares of Common Stock underlying certain
Strategic Advisor Warrants, which are each held by YZi Labs Management as of the date hereof. Each of the Pre-Funded Warrants, the Stapled
Warrants and the Strategic Advisor Warrants either provide or the holder has elected that the holder shall not have the right to exercise
any portion of any such warrants to the extent that after giving effect to such issuance after exercise, such holder and certain of its
affiliates would be deemed to beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 4.99% of
the Company&rsquo;s then outstanding shares of Common Stock (the &ldquo;Beneficial Ownership Limitations&rdquo;). As of the date hereof,
none of YZi Labs Management&rsquo;s Pre-Funded Warrants, Stapled Warrants or Strategic Advisor Warrants are currently exercisable, and
are not expected within 60 days to be exercisable due to the Beneficial Ownership Limitations. </P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> As of the date
hereof, Ms. He may be deemed to beneficially own 2,099,644 shares of Common Stock, consisting of (i) 911,524 shares of Common Stock directly
beneficially owned and (ii) 1,188,120 shares of Common Stock underlying certain Stapled Warrants. As of the date hereof, Mr.&nbsp;Odagiu
may be deemed to beneficially own 4,918 shares of Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> The shares of Common
Stock purchased by YZi Labs Management were purchased with working capital (which may, at any given time, include margin loans made by
brokerage firms in the ordinary course of business). The shares of Common Stock purchased by Ms. He and Mr. Odagiu were purchased with
personal funds. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> Each Participant, as
a member of a &ldquo;group&rdquo; with the other Participants for the purposes of Section 13(d)(3) of the Exchange Act, may be deemed
to beneficially own the shares of Common Stock owned in the aggregate by all of the Participants. As of the date hereof, the Participants
beneficially own in the aggregate 4,255,043 shares of Common Stock. Each Participant disclaims beneficial ownership of the shares of
Common Stock he, she or it does not directly own. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> On July 28, 2025, in
connection with the PIPE, (i) YZi Labs Management entered into a Securities Purchase Agreement and Registration Rights Agreement, pursuant
to which it purchased 2,150,481 shares of Common Stock at an offering price of $10.10 per share, 7,750,510 Pre-Funded Warrants and 9,900,991
Stapled Warrants, and received certain registration rights in connection with the PIPE and (ii) Ms. He entered into a Securities Purchase
Agreement and Registration Rights Agreement, pursuant to which she purchased 1,188,120 shares of Common Stock and 1,188,120 Stapled Warrants,
and received certain registration rights in connection with the PIPE. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> On August 5, 2025,
in connection with the closing of the PIPE, YZi Labs Management entered into the Strategic Advisor Agreement, pursuant to which the Company
engaged YZi Labs Management to provide strategic advice and guidance relating to the Company&rsquo;s business, operations, growth initiatives
and industry trends in the crypto technology sector. Pursuant to the terms of the Strategic Advisor Agreement, the Company issued 3,564,359
strategic advisor warrants (the &ldquo;Strategic Advisor Warrants&rdquo;) to YZi Labs Management, with an exercise price equal to the
par value of the Common Stock. Also on August 5, 2025, YZi Labs Management entered into the SSA, pursuant to which YZi Labs Management
would provide certain strategic advisory services to 10X Capital and receive a portion of the fees earned by 10X Capital under the Asset
Management Agreement. On December 11, 2025, YZi Labs Management delivered a notice of termination of the SSA to 10X Capital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> For information regarding
transactions in securities of the Company during the past two years by the Participants, please see <U>Schedule III</U> attached hereto.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2023, Mr.
Zhao pleaded guilty to a single count of Failure to Maintain an Effective Anti-Money Laundering Program in the U.S. District Court for
the Western District of Washington. Mr. Zhao was sentenced to four months in prison and assessed a $50 million fine. This marks the first
known instance that an individual with no criminal history was sentenced to prison for the same violation involving no allegations of
fraud or identifiable victims. On October 21, 2025, Mr. Zhao received a full and unconditional pardon from President Trump of the above-referenced
conviction. The Trump Administration has since justified Mr. Zhao&rsquo;s full and unconditional pardon by citing the unprecedented nature
of his prosecution and sentencing. When asked about his pardon of Mr. Zhao, President Trump stated that he was informed Mr. Zhao &ldquo;was
not guilty of anything,&rdquo; that &ldquo;what he did is not even a crime,&rdquo; and that &ldquo;he was persecuted by the Biden Administration.&rdquo;
Similarly, White House Press Secretary Karoline Leavitt explained that Mr. Zhao&rsquo;s prosecution was motivated by the previous Administration&rsquo;s
 &ldquo;desire to punish the crypto industry.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Zhao is subject to a consent
order entered in <I>CFTC v. Zhao</I>, et al., in the U.S. District Court for the Northern District of Illinois. The consent order contains
conclusions&mdash;to which Mr. Zhao neither admitted nor denied&mdash;that Mr. Zhao was liable as a control person for certain compliance
violations of the Commodity Exchange Act committed by Binance and individually for willful evasion. This is the first time the CFTC brought
an enforcement action for willful evasion. Mr. Zhao was assessed a $150 million penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2024, Mr. Zhao
was the subject of a Consent Order entered by Washington&rsquo;s Department of Financial Institutions Division of Consumer Services, which
prohibited him participating in the conduct of the affairs of a Washington money transmitter for five years from the date of entry of
the Consent Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 28, 2024, Mr. Zhao
was the subject of an Order of Prohibition issued by Michigan&rsquo;s Department of Insurance and Financial Services prohibiting him from
being a licensee, being employed by an agent of, or a control person of any licensee under the Money Transmission Services Act, or being
a licensee or registrant under the federal licensing act for a period of five years from the date of the Prohibition Order. Mr. Zhao has
since appealed the Prohibition Order, and his appeal is pending in the Michigan 30th Judicial Court for the County of Ingham (case number
24-766-AA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2025, Mr. Zhao
was the subject of a Consent Order entered by the Georgia Department of Banking and Finance prohibiting him from applying for a Georgia
money transmitter license, controlling the affairs of a Georgia money transmitter, and acting as an ultimate equitable owner or executive
officer of a Georgia money transmitter. The stated duration of the prohibition terminates on the later of 5 years from the date of entry
of the Consent Order or until he receives a pardon, the latter of which he already received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2025, BAM Trading
Services Inc. executed a multistate settlement agreement (&ldquo;MSA&rdquo;) collectively resolving enforcement actions of participating
state regulators. Although Mr. Zhao is not a party to the MSA, the order prohibits Mr. Zhao from serving in any managerial role or otherwise
exerting a controlling influence over the management or policies of at BAM Trading Services Inc. or BAM Management US Holdings Inc. By
the terms of the MSA, these restrictions on Mr. Zhao were terminated on October 21, 2025, upon his receipt of a full and unconditional
pardon. Participating states included: Alabama, Arkansas, Arizona, Idaho, Iowa, Kentucky, Maryland, Minnesota, Nebraska, New Mexico, Oklahoma,
Rhode Island, South Carolina, Utah, Virginia, and West Virginia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 3, 2025, Mr. Zhao
was the subject of a Final Order entered by Florida&rsquo;s Office of Financial Regulation (&ldquo;OFR&rdquo;) incorporating the terms
of a Stipulation and Consent Agreement (&ldquo;SCA&rdquo;) executed by OFR, Mr. Zhao, and BAM Trading Services, Inc. The SCA prohibits
Mr. Zhao from being appointed to any role subject to Fla. Stat. 560.141(1)(c) at BAM Trading Services, Inc. and BAM Management US Holdings.
However, the prohibitions have since been lifted according to the terms of the SCA, by virtue of Mr. Zhao&rsquo;s receipt of a full and
unconditional pardon from President Trump on October 21, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Except as set forth
in this Consent Statement (including the Schedules hereto), (i) during the past 10 years, no Participant in this solicitation has been
convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no Participant in this solicitation directly
or indirectly beneficially owns any securities of the Company; (iii) no Participant in this solicitation owns any securities of the Company
which are owned of record but not beneficially; (iv) no Participant in this solicitation has purchased or sold any securities of the
Company during the past two years; (v) no part of the purchase price or market value of the securities of the Company owned by any Participant
in this solicitation is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities;
(vi) no Participant in this solicitation is, or within the past year was, a party to any contract, arrangements or understandings with
any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or option arrangements,
puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies;
(vii) no associate of any Participant in this solicitation owns beneficially, directly or indirectly, any securities of the Company;
(viii) no Participant in this solicitation owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the
Company; (ix) no Participant or any of his, her or its associates or immediate family members was a party to any transaction, or series
of similar transactions, since the beginning of the Company&rsquo;s last fiscal year, or is a party to any currently proposed transaction,
or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved
exceeds $120,000; (x) no Participant in this solicitation or any of his, her or its associates has any arrangement or understanding with
any person with respect to any future employment by the Company or its affiliates, or with respect to any future transactions to which
the Company or any of its affiliates will or may be a party; and (xi) no Participant in this solicitation has a substantial interest,
direct or indirect, by securities holdings or otherwise, in any matter to be acted on in this solicitation. With respect to each of the
Participants, except as set forth elsewhere in this Consent Statement, none of the events enumerated in Item 401(f)(1)-(8) of Regulation
S-K of the Exchange Act occurred during the past 10 years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"> There are no material
proceedings to which any Participant in this solicitation or any of his, her or its associates is a party adverse to the Company or any
of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>OTHER MATTERS AND ADDITIONAL
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Some banks, brokers and other
nominee record holders may be participating in the practice of &ldquo;householding&rdquo; consent statements and annual reports. This
means that only one copy of this Consent Statement may have been sent to multiple stockholders in your household. YZi Labs will promptly
deliver a separate copy of the document to you if you write to our solicitor, Saratoga, at the address set forth on the back cover of
this Consent Statement, or call toll free at (888) 368-0379. If you want to receive separate copies of our consent materials in the future,
or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker
or other nominee record holder, or you may contact our solicitor at the above address and phone number. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SPECIAL INSTRUCTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you were a record holder
of shares of Common Stock as of the close of business on the Record Date for this consent solicitation, you may elect to consent to, vote
against consenting to or abstain with respect to each Proposal by marking the &ldquo;CONSENT,&rdquo; &ldquo;AGAINST CONSENT&rdquo; or
 &ldquo;ABSTAIN&rdquo; box, as applicable, underneath each Proposal on the accompanying <B>WHITE</B> consent card and signing, dating and
returning it promptly in the enclosed post-paid envelope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IF A STOCKHOLDER EXECUTES
AND DELIVERS A WHITE CONSENT CARD, BUT FAILS TO CHECK A BOX MARKED &ldquo;CONSENT,&rdquo; &ldquo;AGAINST CONSENT&rdquo; OR &ldquo;ABSTAIN&rdquo;
FOR A PROPOSAL, THAT STOCKHOLDER WILL BE DEEMED TO HAVE CONSENTED TO THAT PROPOSAL, EXCEPT THAT THE STOCKHOLDER WILL NOT BE DEEMED TO
CONSENT TO THE ELECTION OF ANY NOMINEE WHOSE NAME IS WRITTEN IN THE SPACE THE APPLICABLE INSTRUCTION TO THE ELECTION PROPOSAL PROVIDES
ON THE CARD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>YOUR CONSENT IS IMPORTANT.
PLEASE SIGN AND DATE THE ENCLOSED WHITE CONSENT CARD AND RETURN IT IN THE ENCLOSED POST-PAID ENVELOPE PROMPTLY. YOU MUST DATE YOUR CONSENT
IN ORDER FOR IT TO BE VALID. FAILURE TO SIGN, DATE AND RETURN YOUR CONSENT WILL HAVE THE SAME EFFECT AS VOTING AGAINST THE PROPOSALS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">If your shares are held
in the name of a brokerage firm, bank nominee or other institution, only it can execute a consent with respect to those shares of Common
Stock and only on receipt of specific instructions from you. Thus, you should contact the person responsible for your account and give
instructions for the <B>WHITE</B> consent card to be signed representing your shares. You should confirm in writing your instructions
to the person responsible for your account and provide a copy of those instructions to Saratoga at the address below, so that we will
be aware of all instructions given and can attempt to ensure that those instructions are followed. If you have any questions or require
any assistance in executing your consent, please call Saratoga at the number listed below.</P>

<DIV STYLE="padding: 1pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>If you have any questions,
require assistance in voting your <B>WHITE </B>consent card, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>or need additional copies
of YZi Labs&rsquo; consent materials, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>please contact:</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <IMG SRC="image_005.jpg" ALT="Saratoga Proxy Consulting LLC" STYLE="height: 83px; width: 317px"> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>520 8th Avenue, 14th Floor</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>New York, NY 10018</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>(212) 257-1311</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Stockholders call toll-free
at (888) 368-0379</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Email: info@saratogaproxy.com</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>CERTAIN ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WE HAVE OMITTED FROM THIS
CONSENT STATEMENT CERTAIN DISCLOSURE REQUIRED BY APPLICABLE LAW THAT IS EXPECTED TO BE INCLUDED IN A CONSENT REVOCATION STATEMENT TO
BE FILED BY THE COMPANY RELATING TO THE PROPOSALS DESCRIBED HEREIN BASED ON OUR RELIANCE ON RULE 14A-5(C) UNDER THE EXCHANGE ACT. THIS
DISCLOSURE IS EXPECTED TO INCLUDE, AMONG OTHER THINGS, CURRENT BIOGRAPHICAL INFORMATION ON THE COMPANY&rsquo;S DIRECTORS AND EXECUTIVE
OFFICERS, INFORMATION CONCERNING EXECUTIVE COMPENSATION AND DIRECTOR COMPENSATION, INFORMATION CONCERNING THE COMMITTEES OF THE BOARD
AND OTHER INFORMATION CONCERNING THE BOARD, INFORMATION CONCERNING CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, INFORMATION
ABOUT THE COMPANY&rsquo;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND OTHER IMPORTANT INFORMATION. SEE SCHEDULE I FOR INFORMATION
REGARDING PERSONS WHO BENEFICIALLY OWN MORE THAN 5% OF THE SHARES AND THE OWNERSHIP OF THE SHARES BY THE DIRECTORS AND MANAGEMENT OF
THE COMPANY.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information concerning
the Company contained in this Consent Statement and the Schedules attached hereto has been taken from, or is based upon, publicly available
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>YZILabs Management
Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><BR>
</B> [<FONT STYLE="font-family: Wingdings">l</FONT>]<B>, 2026</B> </P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>SCHEDULE I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The following is reprinted
from the Company&rsquo;s</I> <FONT STYLE="background-color: white">[<FONT STYLE="font-family: Wingdings">l</FONT>] <I>filed with the Securities
and Exchange Commission on </I>[<FONT STYLE="font-family: Wingdings">l</FONT>]<I>. </I></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 42; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>SCHEDULE II</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>PROPOSED AMENDMENT TO THE
AMENDED AND RESTATED BYLAWS OF CEA INDUSTRIES INC.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">1.</TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify">Proposed amendment to Article II, Section .04 of the Bylaws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Article II, Section
.04 of the Bylaws of the Company is amended by deleting the section in its entirety and replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">.04 Vacancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">In case of any vacancy
in the Board of Directors, the remaining Directors, whether constituting a quorum or not, may elect a successor to hold office for the
unexpired portion of the terms of the Directors whose place shall be vacant, and until his/her successor shall have been duly elected
and qualified. Further, the remaining Directors may fill any empty seats on the Board of Directors even if the empty seats have never
been occupied. Notwithstanding the foregoing, a vacancy in the Board of Directors created by an increase in the size of the Board of Directors
by the vote or written consent of the shareholders may be filled only by the vote of a majority of the shares entitled to vote represented
at a duly held meeting of shareholders at which a quorum is present, or by the written consent of holders of a majority of the total outstanding
shares entitled to vote. Each Director so elected shall hold office until the next annual meeting of shareholders and until his/her successor
has been elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"> <B><U>SCHEDULE III</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"> <B>TRANSACTIONS IN SECURITIES
OF THE COMPANY<BR>
DURING THE PAST TWO YEARS</B> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> <U>Nature
    of the Transaction</U> </TD>
    <TD STYLE="font: 10pt/107% Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> Amount
    of Securities <U>Purchased/(Sold)</U> </TD>
    <TD STYLE="white-space: nowrap; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> Date of </P>
    <P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <U>Purchase/Sale</U> </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><U>YZILABS MANAGEMENT LTD.</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>&nbsp;</B> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Common Stock* </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 2,150,481 </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Pre-Funded Warrants* </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 7,750,510 </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Stapled Warrants* </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 9,900,991 </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Strategic Advisor Warrants* </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 3,564,359 </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><U>JIAJIN &ldquo;JANE&rdquo;
HE</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>&nbsp;</B> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Common Stock* </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 1,188,120 </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Stapled Warrants* </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 1,188,120 </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 08/05/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (60) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/09/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (565) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/26/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (16,801) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/27/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (27,916) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/29/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (853) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/30/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (63,121) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 10/31/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (87,092) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 11/03/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (79,971) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 11/04/2025 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Sale of Common Stock </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> (217) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 11/05/2025 </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><U>ALEX ODAGIU</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B>&nbsp;</B> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-indent: 0in"> Acquisition of Common Stock** </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 4,918 </TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in"> 09/24/2025 </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"> *Represents acquisition
of securities in connection with the closing of the PIPE. </P>

<P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> **Represents acquisition of securities in connection with a private
transaction.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>IMPORTANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tell your Board what you think!
YOUR CONSENT IS VERY IMPORTANT, no matter how many or how few shares you own. Please &ldquo;<B>CONSENT</B>&rdquo; to each of the Proposals
by taking three steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 57pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">SIGNING the enclosed <B><U>WHITE</U></B> consent card,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 57pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">DATING the enclosed <B><U>WHITE</U></B> consent card, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 57pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">MAILING the enclosed <B><U>WHITE</U></B> consent card TODAY in the envelope provided (no Postage is required
if mailed in the United States).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>If any of your shares are
held in the name of a broker, bank, bank nominee, or other institution, only it can give consent for your shares and only upon receipt
of your specific instructions.</B> Depending upon your broker or custodian, you may be able to give consent either by toll-free telephone
or by the Internet. You may also give consent by signing, dating and returning the enclosed <B><U>WHITE</U></B> consent card in the postage-paid
envelope provided, and to ensure that your consent is given for your shares, you should also contact the person responsible for your account
and give instructions for a <B><U>WHITE</U></B> consent card to be issued representing your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After signing the enclosed
<B><U>WHITE</U></B> consent card, <B>DO NOT SIGN OR RETURN BNC&rsquo;S CONSENT REVOCATION CARD UNLESS YOU INTEND TO CHANGE YOUR CONSENT
INSTRUCTIONS</B>, because only your latest dated consent card will be counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have previously signed
and returned a [<FONT STYLE="font-family: Wingdings">l</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT> consent
revocation card to BNC, you have every right to change your consent instructions. Only your latest dated consent card will count. You
may cancel any consent revocation card already sent to BNC by signing, dating and mailing the enclosed <B><U>WHITE</U></B> consent card
in the postage-paid envelope provided or by giving consent by telephone or Internet. Any consent revocation may be cancelled at any time
prior to our delivery of written consents to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>If you have any questions
concerning this Consent Statement, would like to request additional copies of this Consent Statement or need help giving consent for your
shares, please contact our consent solicitor:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 1pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>If you have any questions,
require assistance in voting your <B>WHITE </B>consent card, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>or need additional copies
of YZi Labs&rsquo; consent materials, </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>please contact:</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <IMG SRC="image_006.jpg" ALT="Saratoga Proxy Consulting LLC" STYLE="height: 83px; width: 317px"> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>520 8th Avenue, 14th Floor</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>New York, NY 10018</B> </P>

<P STYLE="font: 10pt Franklin Gothic Book,sans-serif; margin: 0; text-align: center; text-indent: 0in"> <B>(212) 257-1311</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Stockholders call toll-free
at (888) 368-0379</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"> <B><I>Email: info@saratogaproxy.com</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in; color: red"><B>PRELIMINARY
COPY SUBJECT TO COMPLETION<BR>
DATED JANUARY <FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT>, 2026 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>WHITE CONSENT CARD<BR>
<BR>
CONSENT OF STOCKHOLDERS OF CEA INDUSTRIES INC. TO ACTION WITHOUT A MEETING:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>THIS CONSENT IS SOLICITED
<FONT STYLE="font-family: Times New Roman, Times, Serif">BY YZILABS MANAGEMENT LTD. </FONT>AND THE OTHER PARTICIPANTS NAMED IN ITS CONSENT
SOLICITATION (COLLECTIVELY, &ldquo;YZI LABS&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>THE BOARD OF DIRECTORS OF
CEA INDUSTRIES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>IS NOT SOLICITING THIS CONSENT<BR>
<BR>
C&nbsp;&nbsp;&nbsp;O&nbsp;&nbsp;&nbsp;N&nbsp;&nbsp;&nbsp;S&nbsp;&nbsp;&nbsp;E&nbsp;&nbsp;&nbsp;N&nbsp;&nbsp;&nbsp;T<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Unless otherwise indicated below,
the undersigned, a stockholder of record of CEA Industries Inc. (the &ldquo;Company&rdquo;), hereby consents pursuant to Section&nbsp;78.320
of the Nevada Revised Statutes with respect to all shares of the Company&rsquo;s common stock, par value $0.00001 per share (the &ldquo;Shares&rdquo;)
held by the undersigned to the taking of the following actions without a meeting of the stockholders of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>IF THIS WHITE CONSENT CARD
IS SIGNED AND RETURNED, IT WILL BE VOTED IN ACCORDANCE WITH YOUR INSTRUCTIONS. IF NO BOX IS MARKED FOR A PROPOSAL, THE UNDERSIGNED WILL
BE DEEMED TO CONSENT TO SUCH PROPOSAL, EXCEPT THAT THE UNDERSIGNED WILL NOT BE DEEMED TO CONSENT TO THE ELECTION OF ANY NOMINEE WHOSE
NAME IS WRITTEN IN THE SPACE PROVIDED. YZI LABS RECOMMENDS THAT YOU <U>CONSENT</U> TO PROPOSALS 1-4.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"> 1 </TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"> Repeal any provision of
                                            the Company&rsquo;s Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;) in effect at the
                                            time this Proposal becomes effective, including any amendments thereto, which were not included
                                            in the Bylaws that were in effect and filed with the Securities and Exchange Commission on
                                            July 25, 2025. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 34%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; text-indent: 0in; font-size: 10pt">Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Against Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Abstain</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"> 2. </TD><TD STYLE="text-align: left; width: 5pt"></TD><TD STYLE="text-align: left"> Increase
                                            the size of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;) by seven (7)
                                            directors to thirteen (13) directors in total pursuant to Article II, Section .02 of the
                                            Bylaws. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 34%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; text-indent: 0in; font-size: 10pt">Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Against Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Abstain</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">3.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Amend Article II, Section .04 of the Bylaws to provide stockholders the exclusive ability
to fill vacancies resulting from an increase in the size of the Board by the vote or written consent of the Company&rsquo;s stockholders
or by court order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 34%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; text-indent: 0in; font-size: 10pt">Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Against Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Abstain</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">4.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"> Elect Max S. Baucus,
                                            David J. Chapman, Teresa Marie Goody Guill&eacute;n, Jiajin &ldquo;Jane&rdquo; He, Alex Odagiu,
                                            Matthew Roszak and Ling &ldquo;Ella&rdquo; Zhang to serve as directors of the Company. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 34%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center; text-indent: 0in; font-size: 10pt">&#9744;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; text-indent: 0in; font-size: 10pt">Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Against Consent</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-size: 10pt">Abstain</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>INSTRUCTION: TO CONSENT,
VOTE AGAINST CONSENTING OR ABSTAIN FROM CONSENTING TO THE ELECTION OF ALL THE PERSONS NAMED IN PROPOSAL 4, CHECK THE APPROPRIATE BOX ABOVE.
IF YOU WISH TO CONSENT TO THE ELECTION OF CERTAIN OF THE PERSONS NAMED IN PROPOSAL 4, BUT NOT ALL OF THEM, CHECK THE &ldquo;CONSENT&rdquo;
BOX ABOVE AND WRITE THE NAME OF EACH SUCH PERSON YOU&nbsp;<U>DO NOT</U>&nbsp;WISH ELECTED IN THE SPACE PROVIDED BELOW.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center; text-indent: 0in"><BR>
<B>__________________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Proposal 1, Proposal 2 and
Proposal 3 are not subject to, or conditioned upon, the effectiveness of the other Proposals. The effectiveness of Proposal 4 is conditioned
upon the effectiveness of Proposal 2. If the size of the Board is not increased, there will be no vacancies to fill, and the Nominees
cannot be elected pursuant to Proposal 4. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>IN THE ABSENCE OF DISSENT
OR ABSTENTION BEING INDICATED ABOVE, THE UNDERSIGNED HEREBY CONSENTS TO EACH ACTION LISTED ABOVE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>IN ORDER FOR YOUR CONSENT
TO BE VALID, IT MUST BE DATED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify; text-indent: 0in; font-size: 10pt">Date:</TD>
    <TD STYLE="width: 46%">
 &#8239;<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
 &#8239;<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Signature of Stockholder</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%">&#8239;<DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Signature (if held jointly)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
 &#8239;<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Name and Title of Representative (if applicable)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt"><B>IMPORTANT NOTE TO STOCKHOLDERS:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Please sign exactly as name appears hereon. If the Shares are held by joint tenants or as community property, both should sign. When signing as executor, administrator, trustee, guardian, or other representative, please give full title. If a corporation, please sign in full corporate name by a duly authorized officer. If a partnership, please sign in partnership name by an authorized person. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>THIS SOLICITATION IS BEING
MADE BY YZI LABS AND NOT ON BEHALF OF THE COMPANY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>PLEASE SIGN, DATE AND MAIL
YOUR CONSENT PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C G(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/.E=#R'P@9CA< 4 ?HG17YPC]MKXKZA\,?AKH2W83QGXA\4ZWH-]XDT/P_\
MVC<>3IVTEX+ ,%:602*,9P K''ITZ_M2?&G4OA[X%\+W*1^$O'7B7QY-X2C\
M5:MHGD[[&-!(MX+)W*I,X8)Y3' 9&''& #[IL]=TW4=0OK"TU"UNKZQ*K=VT
M,RO+;EAE1(H.5R.1G&16;XD^(7A;P;<VUOK_ (ET?0[BY_U$6I7\5N\O./E#
ML"W/I7R;^Q+9ZYI_[47[4-OXFU>S\0:[#?Z+#<ZI8VHMH[G;:2!6\H,P1MNW
M<H. V['%>:?'SX-WGB[]HSXM^*O">@^ OCO"UA:6?B'PCXEG,&K>']D!"BRF
M;Y81(JLX8'.[Z9(!^AMQX@TNUU"QL)M2LX;Z_#-:6LDZ++<!1EC&I.7 !R<9
MP*T*_/;X0_%#P]XB\8?L;CP;HBP^&]0TKQ'#;_\ "11K?:GIYMH2C1173#<%
M#*5RN R!1@=!E_#/]J;XZ7G@7X(_$O7?%VBZEH/C#QLGA"\\.PZ&D+-$]S-%
M]I,X;(D'E'"J N-N<G- 'Z.T5\4>#?C)\8_BQXA\7^-]*^(7@WP9X+\->.)O
M"O\ PBWB&Q5([FW@D1)'EO-V])Y-XV(HVY.*X'4?VROC/KGQ&\::SX6T[4M0
M\/>&/&+^&T\)6OA4SVUY;0RI'-)+J>\&&X(8NL>,#"@@[J /T3DD6&-G=@B*
M-S,QP !U)-4X]<TV;6)=)34+5]4BB$\EBLRF=(R<!RF=P4GC.,5\G_\ !4M-
M<;]E6ZDT?6SI$*ZSIR7D8@WFZB>X5%CSD;0'9'/7<$*G@UYCXGT7XGVO[9_C
M:+PYX\T[2O%>E_"NSGU/Q'/H:3?;9(IF)$=N7V1"1P">6V@8 SR #]#*0G')
MX%?G3-^VQ\4?B)HOP5T;0IKGP_K7B;PK-XBU?5/#WA<Z[<2/'.]NL<5J7 5"
MT;.[9) 8 8[_ %Y^S3\1/%7Q4^ NA>(?&^AMX?\ %,T,T-_:>68U9XW9!*JD
MG:KJH?&3C=CM0!Z=I&M:?X@L5O=+O[;4K-B56XLYEEC)!P0&4D9!!%7:^2?^
M"6:A/V-_#8  ']IZI@#_ *_9:\G^)G[7?Q+\,?%8:GX<\8)XG\'P^.K?PO<Z
M=8^$RFCP0O*$>%M2E<227:YY$09 >>G% 'Z'45\+>-OVL/B%H/P7_:H\10:K
M91:KX!\6'2=!D>SC*PV_G0(%=2,2'$C#+<Y-6/'/QF^-/B7XO?$CPOX2\::5
MX7TOPQX(LO$Z2W&B1WDTD[0%VB&Y@%20@Y8ABH VCDF@#[AJC-KFG6NK6VES
M:A:Q:G=(TD%F\RK-*J_>94)RP'<@<5\0>&_VEOBS\?\ 5/@YX+\*^(M)^'NM
M^)/ K>,-5UY]*6^$LBRF 6\$,C!5!=2[<DA3P>.</QDWQ#\=?M-_LY?9/&WA
M-/&]SX7UV&Z\5Z#;?VCIHV-M>2WC9E#OA0"&.U6+<$#% 'Z$T5X%^Q3\7O%/
MQB^#]Y?>,KBTOO$.CZ]J&A7%_9P>0EW]GEVB7RP<(2",@<<5\W^(OVK/C1-\
M.?B)\=]+\2>'M.\$^#O$TFC+X NM,#2WEM%<1PNTMWNWQSMY@8*!M'H<XH ^
M];OQEH%AXAM- NM<TVVUV\4O;:7-=QK<S* 22D1.YAP>0.QK4DN(H2!)(B$@
ML S <#J?PKX.^!'@O5_$_P#P4B^+OB?5M7L-132]-TR[AAO=#B-S%!=6KF"&
M*4L6@:)2%=EYEP<@9K3^(6G>+[K_ (*96RP>+5AT6+X<3WW]FO8!U%G]H$<M
ML&+<.\H$GG8R  F" #0!]JZ/K6G^(=.AU#2K^VU.PFR8KJSF66)\$@[64D'!
M!''I5VOR[_9&^)'Q0^#_ ,$_V8[R#Q)I5UX#\7^)G\+GPN-*598HYKFX/VDW
M6[<TF]7.T +@J.>:[+P5^V5\9?&OCJ'Q-I>FZEJ7A23QD_A^3PM#X6;['#IZ
MRF)I_P"U-^3=+]\Q8V]>!0!^@&O>)=(\*V'V[6]5LM'LMXC^TW]PD$>XYPNY
MR!DX/'M47AWQAH/C""6;0=;T[6X8B%DDTZ[CN%0GH"4)P:^6?^"G5A;:I\#_
M  =9WD$=U:W'CK1HI895W*Z,\BLI'<$$C\:Y3Q-\.O"G[/\ ^WS\$K3X7:38
M^%5\3:9JT/B;2=* BMY;.&$20RR1#Y5(D!PV!DI[&@#[7;Q%I,>N)HK:G9KK
M+Q?:%T\W""X:/.-XCSN*Y!YQCBL"\^,G@'3[J>UNO''ANVN8':*6&;5[='C<
M'!5E+Y!!!!!K\D_$W[2VAW/[05]^T7;ZCJ\FOZ9XUCL;+3X["X-G+X5CB:VE
M83!/*#N69L%N"3W(KZ8_:0^!OPKU']K[]FUK'P3X=GTOQC>ZU>:L8[&,QZMF
MU65))N,2?,Q<$]VS0!]]Z;J=GK-A!?:?=P7UE<()(;FVD$D<BGHRLI((]Q5F
MLWPYX;TOP?H-CHNB:?;Z5I%C$L%K96D8CBAC'154< #TK2H **** "BBB@ H
MHHH **** "O-?C9^SMX#_:(TW2;'QWI$VJV^E7!N[/R+Z>T:*4KM+!H74]/4
MUZ57S'^WCXR^(_@KP+X8O/!#:]9Z"^L(GBG4_"EC'>:M9V&TG?!&X(^]]YL<
M8'8F@#L/A[^QG\(/A;9^(X/#WA(6\GB*PDTO4KNYOKFZN9K61=KPB:61G12.
MRD= >PK3\3?LK_##QE\//"7@C6/#*7GAWPF\$FC6[7,RR6AB7:F)0X<C'!!8
MAL#.<"OD'PK^U/XI\*_LY?&CQ5X*^)Y^,,&A1V[Z0NN6(MM=T(OE9GOXW6-9
M8U/*E0V=I]U'K6G_ +;WB'24^&WA2Y^$WB7Q%\0/$WAA-<_L^SNK13M60QM)
M(VX(BLJ&4'MO5< G  /7?C1^R7\+?C]JUKJWC+PV;O6+:$VR:E8WD]E<M"<Y
MB>2%U+IR?E;(&3C&:[[P/\//#?PU\'6/A3PQHUKHWAVRB,,&GVZ?NU4DELYR
M6))))))))))S7@?C;]MY?AW\3M/\/>(OAOKNC^'+[7HO#MOXAO+RUB>:XD(5
M98[,OYSV^3_K@,8]^*\_\%?MTZ_X=\1?M!ZM\2O#5_8>$/ ^HI:6'V7[.S1R
M;DCBLP%;=)-,T@D#D[ ."5QB@#V[P1^Q;\(?AWXQL?$FA>&9+:[TV>2YTVSD
MU&YFL=/FDSODM[5Y#%$QR>548SQBNU^,/P/\$_'KPS%H/CC0XM:L(9UNK<^8
M\,UO, 0)(I8V5T;!/*D5XYH_[>'ARS\/^/;GQSX:U+P/K7@_2XM:N]'DNK:^
M>YM)6V1/#+ Y1F,A6,J2-K,H/<BEI_[<FI-XBL_#>L?!WQ/H'B2^\.7WB:RT
M^ZNK9_M=O!$9$1'1C^\< KL8 HV 1R#0!Z'X*_8[^$O@'P9XK\,:7X65].\5
M0FWUN:^NYKFZOX\$!7GD<R8&XXPPP3D<\UGZQ^Q#\(=<\&^&/#5YX?O'M/#2
MRQZ5>)J]VE];1RL6DC%R)1*8VW'Y"Q4 X %0>#_VQ/#WC_5_@YIWA_1K[4;C
MXC:9<:NNV2,#2;>!!YC7'/)$FZ(;>K*:]_H \@\0?LE_"CQ)\,]#\ S^$;>U
M\-:%*+C2H;":6VFL9@23+%/&PD#DDEFW98G)S2^'OV3?A9X5TKPAI^E>%UL[
M?PKJK:WIA2[G+B^9=K7$KE]TSD<$R%N@]!7KU% ''?#OX1^%OA0_B#_A%=.;
M2HM=U*35[VW2>1X3=28\R1$9BL>[ RJ #CI1\/OA'X6^%MYXGNO#6FG3Y_$N
MJ2ZUJC&>27S[N3&^3#L=N<#Y5P/:NQHH Y&/X4^&(OBM+\2%TXCQC+I T)]0
M\^3!LQ+YPC\O=L^_SNV[NV<5Q.I_LA_"C6/ ^J>$KOPN)=&U#6Y?$DB_;)Q-
M%J,ARUS%,'WQ/_N, !D8P:]DHH \5M_V-?A#:_#%_ 2>$8QH$FH#6&<W<_VP
MWXZ7?VK?YWG#IOWYQQTXKLOA'\%?!_P-\.W&B^#M*.G6MU=/?7<TT\EQ<7=P
M^-TLTTC,\CG Y8GI7<44 <5X6^#OA+P7K'C/5-(TQK6^\87(N]:D-Q(_VF4(
M4W ,Q"?*2,+@5Y]<_L1_!^X\*^#O#Z^&KBUT_P )&X&CM9ZM=P3V\<[L\\1F
M242.CLQRK,1SVKW:B@#PBX_8A^#DGA'2?#=OX7FTW3]'OKC4=+ET_4[JWN=/
MFG(,WD3K()(T; R@;;QTKTKX7_"KPM\&O"4/AKPAI2Z3I,<CS&/S'EDEE<Y>
M621R7D=CU9B2:ZVB@#YZ\4?L"_ WQAXRO?$FI^# ]W?W7VZ^LX;^YAL;N?.[
MS);9)!&S$\GY>23G-=#\4OV0_A3\8M<@UCQ+X9,E_':I82OI][<6*W5JI!6W
MG6!T$L8(&%<' X'%>R44 >=^//V>_A]\2K7P?;>(?#5K>VWA&[BO=$A5GB2T
MDC " *A * *OR-E3M&1Q69\8OV7?AQ\=]2M-2\7:'-<:I;6SV2WUA?W%E/);
M.<O;R/"Z&2(DGY&R.3C&37J]% 'GV@_ 3P)X6\8:%XGTC0(M-U?0]#_X1O3G
MMY9%BM]/WA_)$>[8?F&=Q!;WKE;O]C;X17WQ)'CB7PH#K7]HC6&A6]G%B]^.
MEVUH'\DS#KO*9SSUYKVNB@#Y\^,?P!U"S^&OQ%TKX2Z!X?.O?$.ZF?7W\37M
MQ]F;SX6BDN%4!_G7Y,( J]3VP>Z_9S^#-E^S[\$_"?@&RE2Y&CV@CN+I$VBX
MN&)>:7'8-(S$9Z @=J])HH \3^,W[&OPF^/7B:+Q%XN\.23:ZMO]D?4-/OY[
M*6>#_GG*877>N./FR<<=*Z)?V<OAW#8^ K&V\-PV5EX%N?MGA^WM99(DLY<$
M%L*WSDY)._=DDDY/->E44 >4:U^RW\,?$>E>/--U/PQ'?6?CB\2_UR.:XE;[
M1<( $E0[LQ,N!@Q[<$5E^$/V-?A#X)_M[^S_  DL[:_I?]CZLVHWMQ>&_MMV
M[$IED;<V<?/]X!5 ("C'M=% 'AWA3]BWX1^#=!\4:3I_ARXDM_$FG'1]1EO=
M4NKF=['&!;)+)(SQQCLJ$=!Z"N;_ &A_V2K?XN6_P6\/:?:Z>/!7@K58WOM-
MOKB8.]@EOY*QQ,N6+@!<$LIXSNS7TK10!XSH_P"Q]\)-&^&FN> X_"4=UX>U
MRY^VZD+ZZFN+FZN 05F:X=S+O4@;6# KVQDU5L_V+_A'9_#_ %_P:?#<]UH_
MB"[@O=6DN]3NIKN]FA</"TEPTAE(0J,#=@<\<G/N%% ''^(OA+X6\5^/?"/C
M/4]--QXC\*"Y72+OSY%%N+B,1S?(&"ON4 ?,#CMBO/G_ &)_@U)\1CXV;P;$
M=8:__M9K?[5/]A:]SG[2;3?Y)ESSNV=>>O->XT4 <#8? OP7IDGC][?26C;Q
MVS-X@_TF4_:RT1A.,M^[^0D?)M]>M4=&_9O^'WA_4/A[>V.AM#<^ ;.:P\.O
M]KF;['#+&(Y%(+_O,J ,ON([5Z910!XOJ'['OPGU+P1_PBDOAIDTM-7FUZ"2
M&_N([JVOI6W230W"R"2,D]E8#MBG7'['_P );KX3P?#E_"B?\(Q!>_VG$JW4
MPNEO<Y-T+G?YOG')^?=G''3BO9J* /-OA#^SKX ^!-YKEUX)T-M(N-;\@ZC(
MUY/<-<M$K!'8RNQ+G>Q9NK%B6)-<Q\7?V+_A'\</%3^)?%/AJ5]<F@%K=7NG
M:A<63W<(  CF\F11(, #Y@3@ 9P*]PHH \VL?V=?AYI6K> ]1L/#<-A<>!K:
MYM/#ZVLLD<=E%<)LF78&VN67J7!.23G))K+L/V4?AAIG@?PGX0MO#K1^'_"N
MLKX@TBU^W7!-O?+(\HEWE]S?/(YVL2O/3I7KM% 'B.N?L7_![Q'\3&\=ZAX1
M2;79+Q-2GC^USK9W%VGW;B6U#^2\@S]XJ<GDY-2>(?V-_A'XH^(S>-]1\*^=
MK4EY'J-Q$M[<)975U']RXFM5<0R2#^\R$GOFO:J* .2^*GPK\,?&KP+J7@_Q
MAIHU70-0">?;^:\3;D<.C*Z$,K!E!!![5@^&?V<_ ?A'6)-5T[2IQJ4OA^/P
MO)=7%_<3O)I\9)6)B[G)R?OGYCZUZ710!X?K7[%_PCUSP5X5\+R^&YK73_"\
M4L&CSV.IW5O=VD4I)EC%PD@D9&W'*LQ!S7I_@7P!X>^&G@W3?"GAC2X='\/Z
M=#Y%K8V^=L:Y)/)))))))))))).370T4 ?-.C?\ !.CX$>'M2M;[3?"^I6<]
MM<+=1"+Q%J*HL@8.&V>?M^\,XQBMG5/V%?@OK'B#4M9N?"LYNK[5!K31Q:M>
M1V\-]O#FXBA64)'(S*,LJC(R.A(KWVB@#P?QU^P[\&/B1XF\1:[K_A$W=]X@
M"G4DCU&ZA@N)  !,84D""4 ?ZP#=R><DFNWB^ O@B'Q)XBU]-(8:KX@T>/0=
M1F^U2_OK*-"B1[=V%PI(W* WO7H-% 'B'B?]B_X1>+O!OA3PS?>&9(]/\*P-
M:Z/-::C<V]U:PL,/$+A)!(R,.JLQ!KH_#/[-_P .?!NL^#=3T/PU#I=UX0L;
MC3=%%M-(L=K!.<S#9NVN6))+."Q))SDFO3** .1^&OPJ\,_"'1K[2O"NGG3;
M&^U"?5)XS/)+ON)FW2OEV)&3V' ["O/-:_8I^#?B#XB2^-;[P?'+J\UXNHW$
M NYUL;F[4DBXEM0_DO)DDY9#D\G)KW&B@#D=#^%/ACPY\1/$WCG3].,'B?Q)
M#;6^IWGGR,)TMT*0C86VKM4X^4#/?-8_C+]GWP/X\^)GA_Q_J^E32>+-"@:U
ML[^WO9H#Y)8MY<BHX61-S,=K CDUZ-10!Y/I?[+/PTT;PCX$\,VGA]HM%\$:
MHNLZ#;_;9R;2[5W<2%B^Y_FD<[7)'/3@5F?\,;?"+_A92^.?^$44:TNI?VR(
M1>3_ &'[?_S]_9-_D^=WW[,YYZ\U[710!PGQD^"/@[X_>$%\,>.-+?5M%6ZC
MO%@CNI;=A,@8*P>)E;C<>_>N/^'O[&OPB^%MOKR>&_"IL[K7+*33K[49K^YN
M+QK=UVO&D\DC21@C^XPY /85[710!P>G_ WP1IGP=_X59;Z%$G@7^SWTPZ29
M'(,#YW N6W[B6)W;MV3G.:S[7]G+P#9WGPYNDTB9[CX>PR6_AR26^G<V<;Q"
M)E.7_>?(H4>9NQCBO3** "BBB@ HHHH **** "BBB@ HHHH QO$^LZEHMK#)
MINA3Z[([[7B@N(82@QG<3*R@^F!SS7S_ /M!>$?B;\5$\,:KX,@USP#XM\-7
MK7=E=+J%G/8W2NH62&ZMQ.!(A &">5YQU->[^-_^0;#_ -=1_(UQ==5.CSQY
MKG/.KRNUCY<MOV4?B-XFTCXQ:CX]BEU?QW\1M(31I+_2%L;2QL(8P#'B+S]T
MAW*I9F.<# ZYKK_A?\&?BAX6^*G@+QYXHTN/6M2\->#I/"<L.G/:VZ7 -QYD
M4J[K@[=L85"#]Y@2, XKW2BM/JWF1[?R/C+6OV'?B1JGBK5-1%OI\L4WC&+Q
M=;ZE?65G-K,I682"SGO#<Y\A0"%5 .<$\<5U?C3]D;QKXZU#XV:??V$\?@[X
MC7,.KQ6L;V1O=.U.(Q-'(9#<;)(08V!CV@L'Z@CGZBHH^K>8>W\CY)?]EWQ-
MH_PD^*EIXW\!VM_'K^D1V:6/PST32].>WCA99?-C02F2>5I(XW,9;:=F .1C
M@O@'XR^)?BO]H#PU\1]>T?QIXQTSP)X1OK74)K_PVFC")"N$CAC9R;BX8!BX
M4DL0 HP.?O.GM-(Y!:1F*],L>*/JWF'M_(^/OV!?AUKOACQQ\0?B79_#WQ(O
MAJ^N)]*\':?K,D%E-I^FM<R7,R+%*ZE4:61<$==AKZ#LV_:"3P/H6GW%RDGB
M>UUI;O4M96VT\17NG"1V:T2'SL1N4*+YG7Y2>]=XS-(VYF+'U)S24?5O,/;^
M10T'7/BI9_$#Q/J6JZ--J/A.\CMET?0XY+&*73F1")V>;SLR^8V& /W0,5UO
M_"<>)O\ H0-0_P#!E9?_ !VL&BCZMYA[?R-W_A.O$_\ T3[43_W$K+_X]2?\
M)UXG_P"B?:C_ .#*Q_\ CU8=%'U;S#V_D;G_  G7B?\ Z)]J/_@RL?\ X]1_
MPG7B?_HGVH_^#*Q_^/5AT4?5O,/;^1N?\)UXG_Z)]J/_ (,K'_X]1_PG7B?_
M *)]J/\ X,K'_P"/5AT4?5O,/;^1N?\ "=>)_P#HGVH_^#*Q_P#CU'_"=>)_
M^B?:C_X,K'_X]6'11]6\P]OY&Y_PG7B?_HGVH_\ @RL?_CU'_"=>)_\ HGVH
M_P#@RL?_ (]6'11]6\P]OY&__P )OXD_Z$'4?_!C9?\ QZC_ (3?Q)_T(.H_
M^#&R_P#CU8%%'U;S#V_D;_\ PF_B3_H0=1_\&-E_\>H_X3?Q)_T(.H_^#&R_
M^/5@44?5O,/;^1O_ /";^)/^A!U'_P &-E_\>H_X3?Q)_P!"#J/_ (,;+_X]
M6!11]6\P]OY&_P#\)OXD_P"A!U'_ ,&-E_\ 'J/^$W\2?]"#J/\ X,;+_P"/
M5@44?5O,/;^1O_\ ";^)/^A!U'_P8V7_ ,>H_P"$W\2?]"#J/_@QLO\ X]6!
M11]6\P]OY&__ ,)OXD_Z$'4?_!C9?_'J/^$W\2?]"#J/_@QLO_CU8%%'U;S#
MV_D;_P#PF_B3_H0=1_\ !C9?_'J/^$W\2?\ 0@ZC_P"#&R_^/5@44?5O,/;^
M1T?_  FGB'_H1=1_\&%E_P#'J/\ A-/$/_0BZC_X,++_ ./5SE%'U;S#V_D=
M$WC7Q$!QX$U$G_L(67_QZF?\)OXD_P"A!U'_ ,&-E_\ 'JP**/JWF'M_(W_^
M$W\2?]"#J/\ X,;+_P"/4?\ ";^)/^A!U'_P8V7_ ,>K HH^K>8>W\C?_P"$
MW\2?]"#J/_@QLO\ X]1_PF_B3_H0=1_\&-E_\>K HH^K>8>W\C?_ .$W\2?]
M"#J/_@QLO_CU'_";^)/^A!U'_P &-E_\>K HH^K>8>W\C?\ ^$W\2?\ 0@ZC
M_P"#&R_^/4?\)OXD_P"A!U'_ ,&-E_\ 'JP**/JWF'M_(W_^$W\2?]"#J/\
MX,;+_P"/4?\ ";^)/^A!U'_P8V7_ ,>K HH^K>8>W\CH?^$V\2?]"'J'_@QL
MO_CM'_";>)/^A#U#_P &-E_\=KGJ*/JWF'M_(Z ^-O$F/^1#U _]Q&R_^.TW
M_A./$W_0@:A_X,K+_P".U@T4?5O,/;^1O?\ "<>)O^A U#_P967_ ,=H_P"$
MX\3?]"!J'_@RLO\ X[6#11]6\P]OY&]_PG'B;_H0-0_\&5E_\=H_X3CQ-_T(
M&H?^#*R_^.U@T4?5O,/;^1O?\)QXF_Z$#4/_  967_QVC_A./$W_ $(&H?\
M@RLO_CM8-%'U;S#V_D;W_"<>)O\ H0-0_P#!E9?_ !VC_A./$W_0@:A_X,K+
M_P".U@T4?5O,/;^1O?\ "<>)O^A U#_P967_ ,=H_P"$X\3?]"!J'_@RLO\
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M.=$T'6=7OD&CZSJ-OIUOJ$4B&W0S*S)*\A8*(L(26!/4=:L_\+6\$^?H4/\
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M=SSFBO1O[!T[_GSA_P"^:/[!T[_GSA_[YH^L1[!["7<\YHKT;^P=._Y\X?\
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MA7I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&=/XA]%%%=IB%%-+JK!2P#'H,\FG4 %%%% !1110 444UVV*6/04 .HKR/\
MX:"MK?6]1L+W0KRS6W@FGB=G4O*L?7*#E-W\.>M6O"OQR@\4_P!G00Z:5O[F
M[:!X5F#K'&JAFEW <@!E&,=3BN"..P\I<JEKML_+R\].YNZ%1*]CU*BD!R :
M6N\P"BBB@ HHHH **** "BBH;R[BT^SGNIVV00HTDC>B@9)_(4 35D>+M#_X
M2;POJVDAE1KRUD@5GSM5F4@$X[ XKR&/]JJSAL;:XO\ PIJEBUU;6^IVT9EB
MD\RPG21XILJQ D(B<>4?FR, GK7J7@'QQ9?$+P^FL6"-':RRR+$)&!=HPQ"2
M%1RH=0' /.UAD"@#P#QI\-?"/C3Q+-K'B_5]4T;4VC\NYTFXVK%$WD>3)L=H
MSNC*%\;6V_.QZD@=$_P.\*>)XM3OS?7E];:],M[++#,FV5#+-.JHRKD(7GSP
M?^647/'/4^);OQ-X\UN?3;;0I;?PU:RF-I+V[2WCU%P<9;;N<P _PA1O[D+P
MVW;^!]3U!1_:_B-H(L ?8]$C%J@]O,.Z0CZ%:5T.S/)M=^!_AG356YUGQ=J%
MG<3Q);75Q*]M"U["AM_+BV>7A0!:0K^[ +#<#G=4%IX%\!Z9J&E7VG>+[K3[
MO3K>*SBEA:,DVZ1-&T>&C(!?>[,X&[<[8(!Q7OVB^#?#_AV0S6&GV\5RWWKI
M_P!Y.WUD8EC^)K;\U/[Z_G3"S/E'2O@[\,-'M9X(/$DP5DN88FS&'ABFBFBV
M@B/)*K<3$,V3ER3FK&I?"GX9:EXC;63XBDAN)"WF1J4*D;@T*KNC)01$)M Z
MB- <[:^IO-3^^OYT>:G]]?SH"S/G/1?!OAS2=9BO?"-[>:KK$=@=-MM/B4-
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MTTT<0]9&"_SKBKZQMM2A$5PN]58,I#%64CN".0:JQ^'-*C;<;.*1O[TN7/\
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MU"RF&V2WN8Q)&X]U(P:YOP?\(?!G@+S3H7ARQL9)2=\WE^9*1_=WMEMH[+G
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M+JT:E%\M6+B_-6"BBE"EN@S]*LQ$HHHH **** "BBB@ HHHH **** "BBB@
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MUZWQ.VRMLK!1116IQA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQM@IN+JRF@C#' +,A49/;DU,K\KMN:TE&52*GM=7]#YN7_@H-X+90W_".Z\
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M#!<21NS*S%028G=5YP.2.2!UXK3T_P"$/@_2[?4[>TT*W@@U.$6]W&C/MEC
M VXW<9"C.,9QSFK&L?#+PQX@U"^O=0TB&ZNKZ-(;B1V;,B(054X/0%0>.XH
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A,FBB@!5I:** $-)DT44 &33J** "FY-%% !DT444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %: FT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,MG_ &E+9);F,2?=WB0;MO7"YK@-6_9K\1R_LL_%R1/AMJ#^.[SXK2:C8/\
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MX?N[MO&&@>$8/ CPR>)/#%U)8XNA=R$6[7*@CE6W%._!H ]9^!_[8WA7XG>
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M2FTJ'5--%D)RBLLC>6ORH[,"Q3[PW L 36;\1_ACKH_;0^(TNE^#M1@D\:^
M'TS0O&%EI@>TL-2$4P:2:X _<L1A=W4Y4="* /K'PS\:OA_XS\47GAO0/&V@
M:SX@L]WVC2[#4H9KB+;PV45B>._'%<K\?/VGO!O[.MYX,M/%-Y'!/XGU6/38
M/,N(XDMXS_K+J4NPVQ1C&6&>64=Z^*?A+\*==UO4/V<?">A_!76_AUXN^'.I
MQW?BOQ;?:;':VTL*(RSI'<J?]*^TL=V!G&?3)KW[_@H!X,NM73X.^)K?P-?>
M.K+PUXSMKW5K+2M-6^NOL.QQ(HB(RZ%MF5Z$[<T =EX9_;,\&7'Q,^(OA3Q;
MJFB>"H_#.K6NEV%YJFKQ1?VJTT'F[D5]N,9 X+=1R*]3\:?&3P'\-[S3;7Q7
MXRT+PY<ZD<64.J:A%;M<<XR@=AD9(&>E?#'CK]GS5?$VG_MGZK+\.;R]U;7E
MLCX9FN-)+W%RHM@=MKE225? .SNH':N(^*?P5\=Z?X[EU/7?"OBW5]'\3?#K
M2=#M!H?ABWUF:&>.U2.>RE\\$V3&3<_F@#!).<B@#]._$7B;3?"?AG4O$&J7
M26ND:=:27MS='E4A1"[-QU 4$\5\@K^WIX]7P6OQ3E^!6I)\%6<2?V\-8A.I
M"S+;1=FRVY\OOC=TYSCFO8K?X)W^M_L;_P#"J[B\O+?4KOP@VAB?5)$DGA=K
M8QJ)63*L4)"DKD';QFOEF;XA?%BZ_95_X9V_X45XP7XA-HH\*-JK6R#01!L\
MDW?VS=MQY?.,?>[T ?3<?[9WP]U#XOQ_#O2]1AOM6F\-?\)%;W'VF-(I]RAX
MK5 3N,S1$R[<<)@\YX?^S?\ M>>#/CYX+\)7<VKZ)H/C+7K62Z7PG_:L4UY&
MJR.G"?*QRJ;ONC@U\\:!\#=0^"O[4_@^SD\#ZAX@TIOA1;^%K;Q-INE">"'5
M(-P:::7&8F,:;0Y^8AU7ITY#X7_LYZ]X6^#/[(<L'PZOM-\4:3XU%YXBD72F
M2\M8#+/NDNFV[E3;Y?+\8V^U 'W[%\9/ <WCQ_!,?C+0G\7H"6T)=1B-X,#)
M'E;MV<<XQG%)8?&;P'JGBR/PO9>,M"N_$DDL\"Z3#J$3W1DA_P!<OEAMV4_B
M&.*_-CP!^SOXYLOB!8^#_$7A_P :+K]K\1&\1C6]+\/68LC'YQ=;\ZN_[QE*
M\-#G<>F,C%?5'[&/P;/AGX@?'7Q7XB\&?V7KNH>/]2FTO5-0T\)/+8,J['@D
M9=WE,6DY4X.30!J?'3]M6'X(_M-_#_X57GAK[98>*(;:2;7?M9061GN9+=,Q
M[#D;T7DL/O5%X+_;<@\:_MB>)/@C:^&A'8:+%<%_$9O<K)-!'$TL?E[,#:TA
M4G=QM]Z\E_;;^!/B_P"*GQZ\1ZEH7A[5+M++X6F;2M2M;9FB.K6VJBZAMT?&
M#,P3A.I#5PGP/^"?Q-\+>+O"OB_4O =]J?BG6/!/BG5]8AU*R>.VEU:\N'>*
MSN"<;"ZK&NUB#@^U 'WMX=^/GP]\<WFK:=X3\;>'?$VLZ=#)+-I^G:K#+(FS
M()8*QPN1@MT%8_@O]H30KCX)^'_B%X\U/P_X&MM20ES)KD$]FC[V4)'<@A)2
M0N?E]QVKX/\ @CX(\9GXV?"[Q3JG@GQ'H&G:?X9UJPU<S>$(=#TK2;AK-R+>
M+RUWM$&R!-,Q#$C:0=P$/PC\'ZK:?!_]E#XCZAX$U+XF_#[P[I6K6VI:#I5D
MM]/:7$\\@BNQ:G_6CC!_N[<^E 'Z/W'QC\!VOAC2_$<WC/08O#^J2"*QU5]1
MA%M<N02%CDW;6.%;@'^$^E9GC+XT:-H_P-\0?$WP[<V?BS1M.TFZU2VDL+I6
MAO!"CDJLJY&"4*Y&<$&OS\E_9R\8>(OA[X<\_P"&NJ:9X3\1?&ZU\10>#)+3
MS&TC16C=)'N8ER($;^).B@CUK[M_:$\%[OV8?B)X8\*:&H:7PW?6NGZ1I-J%
MW.T+A8XHD&,ECP .IH \*\*_M[>+[/2? WBKXC?!V;PA\./&$EK%8^*K'7(K
M](&N!F!IX0BO&K9&2>GZ5[_X;^,Z7GBSXF6.OIH^@Z'X.FMU_M5M9AD+QR0^
M8SW$?!MMIX <_,.17P\UE\1/C_\ LS?"S]GVR^#_ (W\*7.G'2(-=\3>*-/6
MQT^UAM-IEDA9F+2$E/E7:"?2I_V@O@OXTUT?M3W$6B30V&I>*?#>I6D&I,+2
M#7[:WB'G00RR$(YSC@'EE ') H ^U-1_:.\$ZEX*U_5_!7BKPSXPU+3]'N=8
M@L+;6[=%FCA!!9Y-Q$4>\!3(PPN>:Y/PW^V3X1U'XE> OAYJLMEIWB[Q/H$>
MM21PZG!/:VTD@3R[595/[V1]Q*[1\RKN'45\9ZE"_P 1OV@OC7_PC7PIU7P%
M<:Q\$+Z&T\-7&GQ07MW*S^6KFWA+;69@(U4_,PC4XY%=SX,^&_B'X?\ QD_9
MW\0WOPNU3567X7P:!+*ND[Q8:NH4Q_:W(S!M VF1N5!..AH ^V_#OQT^'7B[
MQ=<^%=$\<^'M6\26Y<2Z39ZG#+<H4^^/+5B<KWXXKGOV9?CLW[0_PYNO%#Z.
M-#,.KWNE_91<>=GR)3'OW;5^]C.,<>IKX)^#G@'X@:E\:/@-KFH?#?Q!X:?0
M=?U!-:T_3_!L&E:1HPF20*L4L8,UPC$Y:9W9!D=">?KK_@G[X,U_P+\"]0TW
MQ'HU]H6H/XFU:Y6UU"!H9#$]P61PK#.UAR#WH ^EJ*** "BBB@ HHHH *XF/
MXU>")OBK+\-4\1VC>.8K07SZ+\WG"$@'=G&W."#MSG!SC%=/KVN67AG0]1U?
M4IUM=.T^WDN[F=^D<2*6=C[  FOQOMOB%XGT_5;+]II_AIXPCUAO&S^(KKQ4
MUJO]F-X<D06PLPP?<<)@ E<9)]J /V?HK\U/VI?BKXRM?C!XP\3Z;XXUK6/
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M/_@=%_\ &Z/^$6MO^AY\<_\ @=%_\;JY11]6IA[>93_X1:V_Z'GQS_X'1?\
MQNC_ (1:V_Z'GQS_ .!T7_QNKE%'U:F'MYE/_A%K;_H>?'/_ ('1?_&Z/^$6
MMO\ H>?'/_@=%_\ &ZN44?5J8>WF4_\ A%K;_H>?'/\ X'1?_&Z/^$6MO^AY
M\<_^!T7_ ,;JY11]6IA[>93_ .$6MO\ H>?'/_@=%_\ &Z/^$6MO^AY\<_\
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MNKT[]GG]I%/CUJ=Y$GAB[T6P^R)J-A>2.[K<6[3/$%?,:A9?D#%5+KAOO9!
M[V]^$_@O48O*N?"NDRQ[K1POV90 UJ"+4C&,>4"0N.@)%6?"OPZ\+>!K[4KW
MP[X>T[1+S4G\R\GL8!&T[9+?,1VRS' XRQ..:J,9IZL3<;:(^,OA_P#M,?%!
MX=+U/7=9NSINMV7B(03:AIMFMHUS9QSO;+9M"?-+#R26\]0I"L!R1FG-^V'\
M2I_ VJP7,R:-XQT/P.FI7ZK9QND]U+>V@MKR'<NTK+;7'W?NA]P(&*^O]'^
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MI63]VVYGW;E7CG@GO7ONK>!?#NO^$E\+ZGHUGJ/AU88K<:;<QAX=D>/+&/\
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MU_#']K7Q+I?@/1)_%>D_\)'<6]CI.I>(]86]A@D@35)S':BUMUB7S@HP6'!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJCA5^1.F/NCTKHZ* *&@Z#I_A?1[32=)M([#3K2,106\(PJ*.P_Q[YJ_110
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MZ<T7\FK_ (NWW/T"]!]&ON+!E01ERZA,9W9X_.H&U2S2(R-=0B,=6\P8K/\
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MFTT'3+;3["!;:SMD$<42=%45<HH **** "BBB@ HHHH **** "BBB@ HHHH
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M:A_8^N1Q^2TC1^9#<1CHDJ9&<9."#D50DM?B191N(K_P_J1VEPTUO+"V1_
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MFV[=[$DLV.V236U10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMN3YR_N3Z/S\OXU/:7D%_;I<6L\=S XRLL+AE;Z$<&@":BBB@ HHHH ****
M"BBJEYJUCI\L,5U>6]M),=L232JA<^B@GGKVH MT5 M];,VT7$1;S/)P'&=^
M,[?KCG'7%1?VQ8?:H[7[;;_:9&94A\U=[%?O #.21W]* +E%47US38[>YN'U
M"U6"U<QSRM,H6)AU5SG"GD<'UITFLZ?#<6]N]];)<7 W0Q-,H:0>JC.3^% %
MRBBB@ HHHH **** "BBD9@JDDX Y)- "T5G6WB/2;R.22WU2SGCCQO:.X1@N
M3@9(/'-6FO;>-9&:>)5C8(Y+@!6., ^A.1Q[B@">BJ']OZ9]CDN_[1M/LL<G
ME//YZ[%?.-I;. <D#%3-J5HMZ+,W4(O/+\W[.9!YFSINVYSCWH LT55T_5;+
M54=[*\M[Q$;:S6\JN%/H<'@U:H **** "BBB@ HHHH **;)(D,;R2,L<: LS
M,<  =234$&I6=U%;RPW4$L=S_J'CD#"7@GY2#\W )X]* +-%59-5LH8%FDO+
M=(65F61I5"D 9)!ST !)^E-76+!A:%;ZV(O/^/8B5?WW&?DY^;CGB@"Y15+^
MV].VW;?;[7;9G;<GSEQ"?1^?E/UJ>TO(+^W2XMIH[B!QE)87#*WT(X- $U%%
M% !1110 4444 %%%1-<Q(SJTJ*R+O=2PRJ\\GT'!Y]C0!+14#7ULN,W$0W1F
M89<<H,9;Z#(YZ<U%=ZQ8:?$9;J]M[:,)YA>:55 7(&[)/3) S[T 7**K?VE:
M&ZCMA=0FYDC\U(?,&]D_O 9R1[U ?$6E"R>\.IV8M$<Q-<?:$\L..JELXS[4
M :%%,CE2:-)(W62-P&5E.00>A!I] !1110 4444 %%%% !1110!YC^TMX#_X
M61\#O&&B+:WE_<R:?-);6=E,\;SSJC&-#L(+ MM^4\' S7F?Q<^$^I?$KP#\
M5I;O2M1GO6MK6PT>RA=X9+D6L(<'"D;T:>:4[3PWEC(.*^FJ* /DSXZ^'[_4
M-4UW4[CP!J'B>_U._70]+NFTN2_@TBRCM2);YK=3^])>:<1J1RQ!RH!-<U)\
M-;K1=2DBD\#>)]?-I>27\FI?9F%S?Z"-%%NM@9LJWG/*%0P9!# OQUK[8HH
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M_P 8_P#@CEH_X7)#_P!"?XQ_\$<M 'H5%>>_\+DA_P"A/\8_^".6C_A<D/\
MT)_C'_P1RT >A45Y[_PN2'_H3_&/_@CEH_X7)#_T)_C'_P $<M 'H5%>>_\
M"Y(?^A/\8_\ @CEH_P"%R0_]"?XQ_P#!'+0!Z%17GO\ PN2'_H3_ !C_ .".
M6C_A<D/_ $)_C'_P1RT >A45Y[_PN2'_ *$_QC_X(Y:/^%R0_P#0G^,?_!'+
M0!Z%17GO_"Y(?^A/\8_^".6C_A<D/_0G^,?_  1RT >A45Y[_P +DA_Z$_QC
M_P"".6C_ (7)#_T)_C'_ ,$<M 'H5%>>_P#"Y(?^A/\ &/\ X(Y:/^%R0_\
M0G^,?_!'+0!Z%17GO_"Y(?\ H3_&/_@CEH_X7)#_ -"?XQ_\$<M 'H5%>>_\
M+DA_Z$_QC_X(Y:/^%R0_]"?XQ_\ !'+0!Z%17GO_  N2'_H3_&/_ ((Y:/\
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M/_@CEH_X7)#_ -"?XQ_\$<M 'H5%>>_\+DA_Z$_QC_X(Y:/^%R0_]"?XQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 3T# 2(  A$! Q$!_\0
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MUQ*\1 *]PR9&#TY%>D?#+Q+J/BSPS)J.J>2)?M#1J(EVC: ON>Y- '8444E
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MW@BQL[U2EP=TKH>J%CG% '554U34K?1],N+^\?9;VZ%W(ZX%6ZY_QWHT^O\
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M%GAD"R7??6;F6%/[XQAE^IX_*O'?!WC_ %7P!-<V;6HE@=LR6TV4*..,CT-
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MFG=K@H>JAN@/X '\:ET3X7^%]"N%N+>P\Z=#E9+AC(5/J!TS^%=;0 M)2T4
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M ("*NV/B5K?3HK&\L+._@@<O +A3F(GJ 01\I/.#74_\*/\ %7_3C_W_ /\
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MEJ7@>W98E."K#!/)/-=;_P */\5?]./_ '__ /K4?\*0\5?]./\ W_\ _K4
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 3T# 2(  A$! Q$!_\0
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MUQ*\1 *]PR9&#TY%>D?#+Q+J/BSPS)J.J>2)?M#1J(EVC: ON>Y- '8444E
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MW@BQL[U2EP=TKH>J%CG% '554U34K?1],N+^\?9;VZ%W(ZX%6ZY_QWHT^O\
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M%GAD"R7??6;F6%/[XQAE^IX_*O'?!WC_ %7P!-<V;6HE@=LR6TV4*..,CT-
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MFG=K@H>JAN@/X '\:ET3X7^%]"N%N+>P\Z=#E9+AC(5/J!TS^%=;0 M)2T4
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M ("*NV/B5K?3HK&\L+._@@<O +A3F(GJ 01\I/.#74_\*/\ %7_3C_W_ /\
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MEJ7@>W98E."K#!/)/-=;_P */\5?]./_ '__ /K4?\*0\5?]./\ W_\ _K4
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 3T# 2(  A$! Q$!_\0
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MUQ*\1 *]PR9&#TY%>D?#+Q+J/BSPS)J.J>2)?M#1J(EVC: ON>Y- '8444E
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MW@BQL[U2EP=TKH>J%CG% '554U34K?1],N+^\?9;VZ%W(ZX%6ZY_QWHT^O\
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M%GAD"R7??6;F6%/[XQAE^IX_*O'?!WC_ %7P!-<V;6HE@=LR6TV4*..,CT-
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MFG=K@H>JAN@/X '\:ET3X7^%]"N%N+>P\Z=#E9+AC(5/J!TS^%=;0 M)2T4
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M ("*NV/B5K?3HK&\L+._@@<O +A3F(GJ 01\I/.#74_\*/\ %7_3C_W_ /\
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MEJ7@>W98E."K#!/)/-=;_P */\5?]./_ '__ /K4?\*0\5?]./\ W_\ _K4
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 3T# 2(  A$! Q$!_\0
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MUQ*\1 *]PR9&#TY%>D?#+Q+J/BSPS)J.J>2)?M#1J(EVC: ON>Y- '8444E
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MW@BQL[U2EP=TKH>J%CG% '554U34K?1],N+^\?9;VZ%W(ZX%6ZY_QWHT^O\
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M%GAD"R7??6;F6%/[XQAE^IX_*O'?!WC_ %7P!-<V;6HE@=LR6TV4*..,CT-
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MFG=K@H>JAN@/X '\:ET3X7^%]"N%N+>P\Z=#E9+AC(5/J!TS^%=;0 M)2T4
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M ("*NV/B5K?3HK&\L+._@@<O +A3F(GJ 01\I/.#74_\*/\ %7_3C_W_ /\
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MEJ7@>W98E."K#!/)/-=;_P */\5?]./_ '__ /K4?\*0\5?]./\ W_\ _K4
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !3 3T# 2(  A$! Q$!_\0
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MUQ*\1 *]PR9&#TY%>D?#+Q+J/BSPS)J.J>2)?M#1J(EVC: ON>Y- '8444E
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MW@BQL[U2EP=TKH>J%CG% '554U34K?1],N+^\?9;VZ%W(ZX%6ZY_QWHT^O\
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M%GAD"R7??6;F6%/[XQAE^IX_*O'?!WC_ %7P!-<V;6HE@=LR6TV4*..,CT-
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MFG=K@H>JAN@/X '\:ET3X7^%]"N%N+>P\Z=#E9+AC(5/J!TS^%=;0 M)2T4
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M ("*NV/B5K?3HK&\L+._@@<O +A3F(GJ 01\I/.#74_\*/\ %7_3C_W_ /\
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MEJ7@>W98E."K#!/)/-=;_P */\5?]./_ '__ /K4?\*0\5?]./\ W_\ _K4
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
